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Granulosa cell tumours (GCTs) are a subtype of ovarian cancer derived from the 
granulosa cells (GC) surrounding the oocytes. The SWR mouse is a well defined model 
for juvenile-type GCTs in terms of endocrinology, genetics and malignancy. GCTs 
appear spontaneously in SWR-derived female mice at puberty, characterized by rapid, 
benign growth followed by a malignant transition after 6-10 months in approximately 
half of the tumour-bearing population. Our aim is to characterize the protein expression 
profile of early GCTs, normal ovaries and the human COV434 JGCT cell line to 
determine if protein expression differences can help identify the mechanism of 
tumourigenesis. This was accomplished using immunoblotting to define the protein 
expression profile of mouse primary GCTs, normal, whole ovaries and human COV434 
cell lysates. Protein lysates from the early GCTs were positive for expression of Cyp19a, 
Fshr, Egfr, Esr2, Foxl2 and Sox9 proteins, with significant downregulation of Esr2 and 
significant upregulation of Egfr in GCTs relative to both normal ovaries. A further 
evaluation of Sox9 was done by immunohistochemistry, which confirmed a proportion of 
cell specifically express Sox9, although the cellular identity is not conclusively that of 
GCT cells. Protein lysates from the COV434 cell line compared to the mouse GCTs were 
also positive for expression of Cyp19a, Fshr, Egfr, Esr2 and Foxl2 proteins, with 
significant upregulation of Cyp19a, significant downregulation of Egfr and Esr2, and no 
Sox9 protein expression. A further evaluation of Sox9 was done by 
immunohistochemistry and confirmed its expression in GCTs. The protein profile of 
GCTs, as compared to normal ovaries and a human representative cell line will provide a 
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1.0 Introduction: Overview of the female ovary and its reproductive functions 
 
The ovary is the female gonad or reproductive gland of many species (Figure 1.1). In 
mammals it is a paired organ residing in the abdominal cavity and has two main 
functions: the production of oocytes, the female germ cells, and the production of steroid 
and protein hormones, primarily the steroid hormones estrogen (E2) and progesterone 
(P4). A specific population of somatic cells called granulosa cells (GCs) nurtures the 
female germ cell, the oocyte, in the female gonads. GCs provide support to the 
developing oocytes in the context of individual ovarian follicles and are necessary for 
their maturation into competent gametes (Adashi & Leung, 1993).  
In humans, puberty is defined by the activation of ovarian cyclicity and the beginning 
of female reproductive potential. Puberty marks the onset of the production of sex 
hormones by the ovary, which in turn allows for controlled ovulation of oocytes 
competent for fertilization and embryonic development. At the end of reproductive life, 
there is a normal decline in the number of available oocytes able to mature for ovulation 
(Adashi & Leung, 1993). This can be attributed to there being a limited starting pool of 
follicles in the fetal ovary, leading to a perimenopausal period of reproductive decline 
(Tingen et al., 2009). This marked and natural reproductive senescence is referred to as 
menopause in humans, a time when ovulation ceases and hormone production is 
drastically reduced by the ovary. Aside from the natural reproductive senescence, 







Figure 1.1 Anatomy of the ovary 
 
The anatomy of the human ovary is complex with many components. A layer of surface 
epithelium surrounds the ovary, which has a central medulla and an outer cortex 
populated with follicles. The post-pubertal, pre-menopausal ovary contains follicles at 
various stages of the maturation cycle, including: primordial follicles primary and 
secondary follicles, antral follicles and mature (vesicular) follicles ready for ovulation. 
The corpus luteum (CL) is a hormone-secreting collection of luteinized granulosa cells 
formed from post-ovulatory follicles, while the corpus albicans is an inactive remnant of 








leading to reduced fertility or pathological outcomes. These variations may be inherited 
germline mutations that are present in all cells of the body, or they may be acquired 
throughout the lifespan in a subset of cells, and therefore defined as somatic mutations. 
By understanding ovarian development, functioning and maintenance throughout the 
reproductive years of life, we can better understand how any genetic alterations, whether 
germline or somatic, contribute to aberrant ovarian function, specifically ovarian 
tumourigenesis, in both mice and humans. 
	  
1.1 Overview of sex specification of the mammalian gonad 
1.1.1 Sex chromosomes dictate gonadal sex 
 
During the early stages of embryogenesis, reproductive development has two 
potential fates: to follow the male pathway with specification of testes and development 
of the Wolffian ducts, or to follow the female pathway with specification of the ovary and 
development of the Müllerian ducts (Kobayashi and Behringer, 2003). The pathways of 
primary gonadal sex determination are initiated by gene expression from the mammalian 
X and Y sex chromosomes (Chr), with Chr XY inheritance establishing male 
development and Chr XX inheritance establishing female development. Following gonad 
specification, unique gonadal structures, supporting cells and sex hormones influence the 
production and development of the sex-specific germ cells, sperm in males and oocytes in 
females (Eggers et al., 2014). Supporting somatic cells of the developing testis are named 
Sertoli and Leydig cells, while in the ovary they are named granulosa cells (GCs) and 








Figure 1.2 The bipotential gonad and determination of sex 
 
In early sex determination, at approximately embryonic day (E) 10 in mice, primordial 
cells have the potential to develop into either the male gonad (XY) or the female gonad 
(XX). Wt1 and GATA4 promote the expression of SRY. SRY acts to stimulate SOX9, 
which prompts the male gonad to develop (E10.5-12.5). FGF9 also acts in male gonad 
development to maintain the expression of SOX9. During male gonad development, 
AMH is expressed which causes the regression of the female Müllerian ducts and in the 
presence of androgens the formation of the Wolffian ducts. In the absence of SRY and 
the presence of CTNNB1, a pathway that is stimulated by WNT4 and RSPO-1, the 
female gonad develops (E10.5-12.5). After the ovary has developed (~E13.5), CTNNB1 
expression declines and other factors, including FOXL2, ESR1 and ESR2 act to 
continually repress SOX9 and maintain the ovarian phenotype. CTNNB1 also promotes 
the formation of the Müllerian ducts in the absence of AMH. 
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The fate of the bipotential gonad is established early in fetal development. The, 
bipotential gonad (Figure 1.2) persists up to day E10 in mice and up to gestational week 
(wk) 9 in humans (Wunsch & Schober, 2007). Primary sex determination subsequently 
takes place between E10.5-12.5 in mice and gestational wk 9-12 in humans, involving 
several key transcription factors and a nuclear receptor network that regulate the 
development of the bipotential gonad into its sex-specific form (Wunsch & Schober, 
2007). 	  
1.1.2 Testis development from the bipotential gonad 
 
The male pathway and testis development from the bipotential gonad proceeds 
with Chr XY inheritance. Chr Y is a relatively small chromosome comprised of only 183 
protein coding genes in the mouse and 63 in humans (GRCh38.p10: Ensembl Release 
90). One of the most influential genes on Chr Y in mice and men is the Sex-determining 
Region of Chr Y (SRY) gene. This gene is initially regulated by the cooperative 
expression of the transcription factors Wilms’ tumour 1 (WT1) and GATA binding 
protein 4 (GATA4; Tanaka et al. 2014). The expression of SRY occurs at approximately 
E11.0 in mice and as early as 41 days post-conception in the cells of the genital ridge in 
humans (Hanley et al. 2000; Tanaka et al. 2014). The expression of SRY is important in 
the early stages of gonad development to trigger a signaling cascade that leads to the 
recruitment of SRY-box 9 (SOX9)-expressing pre-Sertoli cells and subsequently inhibits 
ovarian differentiation (Tanaka et al. 2014). Following its activation by SRY, SOX9 
expression is maintained in the developing testis by Fibroblast Growth Factor 9 (FGF9) 
along with other factors. The expression of SOX9 helps to sustain testis development by 
acting in a positive feedback loop, as well as acting to promote Sertoli cell proliferation 
6	  
(Wilhelm et al., 2007; Tanaka et al. 2014). Table 1.1 outlines these genes and others 
involved in the development and determination of the bipotential gonad, as well as 
describing phenotypes involved with loss of function of these genes. Using mouse as a 
model organism,when Sry loss of function occurs in Chr XY gonads, male-to-female sex 
reversal is observed; conversely, when Sry is overexpressed in the Chr XX gonads, 
female-to-male sex reversal occurs (Koopman et al. 1989). A similar result arises when 
there is loss of function in the Sox9 gene, and male-to-female sex reversal ensues, with 
abnormal development and differentiation of the Sertoli cells (Huang et al. 1999). The 
outcomes of these loss-of-function mutations in the Sry and Sox9 genes demonstrate their 
importance in normal testis development. 
The development of the mature Sertoli cells regulates the formation and 
differentiation of the Leydig cells, which produce the male sex hormone, Testosterone (T; 
Sekido et al. 2012). The production of T and subsequently dihydrotestosterone by the 
Leydig cells then act as ligands for the androgen receptor (Ar) to develop secondary sex 
characteristics such as the external genitalia (Tanaka et al. 2014; Sekido et al. 2012). The 
expression of SOX9 by the Sertoli cells also leads to Anti-Müllerian Hormone (AMH) or 
Müllerian Inhibiting Substance (MIS) being expressed to cause the regression of the 
Müllerian ducts in female embryos (Koopman et al., 2001), in turn allowing for the male 
counterpart, the Wolffian ducts. The Wolffian ducts will later form components of the 
male reproductive system, including the epididymis and seminal vesicles (Wilhelm et al., 
2007). These components, along with the Sertoli cells and T-producing Leydig cells will 
later aid in the differentiation and maturation of the germ cells into mature sperm (Tanaka 
et al. 2014). 
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1.1.3 Ovary development from the bipotential gonad 
 
It was initially thought that the female (or ovarian) fate of gonad development 
was the default pathway when the sex chromosomes and genes necessary for male 
development were not present. This hypothesis was developed by investigating the fate of 
the population of supporting cells in the developing gonad using several different models 
including transgenic and mutant mice, cultured gonads, and transplanted and chimeric 
gonads (McLaren, 1991). These studies concluded that in supporting cells where the 
male-determining gene was expressed in a sufficient quantity, pre-Sertoli cells would 
develop and therefore proceed to the testis pathway. When the male-determining genes 
was not expressed in a sufficient number of supporting cells, or was not expressed at the 
appropriate time in development, the cells would differentiate into pre-follicle cells, now 
referred to as GCs (McLaren, 1991). This hypothesis has changed over time as a 
reflection of research progress. Forkhead box L2 (FOXL2), a transcription factor that 
belongs to the forkhead/winged helix transcription factor family, was determined to be 
expressed in the female gonad in the early somatic cells, it was subsequently considered 
to be the female determining gene, similar to SRY and SOX9 in the male pathway 
(Georges et al. 2013).  
Ovaries that develop from the bipotential gonad are selected with Chr XX 
inheritance. Once the bipotential gonad has initiated the female sex determination 
pathway, the downstream signaling events important for female sex specification 
proceed. The activation of the Wingless-type MMTV integration site family member 4 
(WNT) /β- catenin (CTNNB1) pathway, regulated by R-spondin 1 (RSPO-1) occurs 
between E10.5  
8	  
 
Table 1.1 Genes involved in the development of the bipotential gonad and male/female 




*TF- Transcription Factor, NR- Nuclear Receptor, H- Hormone, GF- Growth 
Factor, SM- Signaling Molecule 
Gene Protein 
Function 











TF 615542 Failure in thickening of 
the coelomic epithelium, 
defective initial formation 
of genital ridge 
Lourenco et al., 
2011 
Wt1 
TF 194080, 136680 Disruption of seminiferous 
tubule and somatic cell 
apoptosis, XY sex reversal 
Gao et al., 2006 
Sf1 
NR 273250 Delayed organization of 
male testis cord, failure in 
genital ridge formation 
Reuter et al., 
2007 
Sry TF 400044, 400045 XY sex reversal; XX sex reversal 
Koopman et al., 
1989 
Sox9 
TF 114290 Abnormal Sertoli cell 
differentiation, XY sex 
reversal; XX sex reversal 
Huang et al., 
1999 
Amh H 400044 XY sex reversal - 
Fgf9 GF 400044 XY sex reversal Jameson et al., 2012 
Wnt4 
SM 158330 Failure in the formation of 
coelomic vessel and germ 
cell degeneration of the 
female reproductive tract, 
partial XX sex reversal 
Yao et al., 2004 
β-catenin TF - Partial XX sex reversal Chassot et al., 2008 
Rspo1 GF 610644 Development of ovotestes, partial XX sex reversal 
Chassot et al., 
2008 
Foxl2 
TF 110100 Premature ovarian failure, 
ablation of the primordial 





and E12.5 in mice and 6 to 9 wks post-conception in humans. As well as being a key 
factor in the ovarian pathway, CTNNB1 also counteracts the male pathway by not only 
disrupting SOX9 but also acting to suppress the development of male-specific coelomic 
blood vessels, subsequently allowing the Müllerian ducts to become the female 
reproductive structures, including the oviducts, cervix and uterus, while the Wolffian 
ducts regress (Chassot et al., 2008; Boyer et al., 2010). Foxl2 along  
with Estrogen Receptor α (Esr1) and Estrogen Receptor β (Esr2) work to repress Sox9 
and prevent the trans-differentiation of the ovary and its cells to the program of the male 
gonad (Uhlenhaut et al., 2009); interestingly, studies looking at conditional inactivation 
of Foxl2 results in GCs being trans-differentiated into Sertoli cells and an upregulation of 
Sox9 and other testicular genes (Tanaka et al. 2014). After the ovary is fully developed, 
Ctnnb1 expression declines and Foxl2, Esr1 and Esr2 function to maintain the ovarian 
phenotype (Figure 1.2).  
When FOXL2 mutations occur in the human population, they were found to be 
associated with blepharophimosis-ptosis-epicanthus inversus syndrome (BPES; OMIM 
110100), which leads to eyelid malformations, and in some cases, premature ovarian 
failure (POF), but not ovary to testis sex reversal (Crisponi et al., 2001). The absence of 
sex reversal in these patients indicates that although FOXL2 is important in the 
development and functioning of the ovary, it is not solely responsible for early ovarian 
differentiation (Mork et al., 2012).  
In addition to studying humans, the mouse has been an excellent model to identify 
the primary determinants and maintenance factors that influence mammalian ovary 
specification, with strong translational value to the normal development and physiology 
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of the human ovary. Mice also present us with the opportunity to alter relevant and 
important genes to determine effects of aberrant function in the ovary. For instance, the 
mutation of Foxl2 in mice has initiated POF and BPES (Uda et al., 2004). These 
conditions, POF and BPES, have phenotype similarities in mice and the humans, 
including the disturbance of follicle formation and malformation of the eyelid, suggesting 
that a mouse model accurately mimics the human condition allowing for the investigation 
of ovarian function (Table 1.1).  
1.2 Ovarian Physiology Over the Lifespan 
	  
1.2.1 The pre-pubertal ovary 
	  
The early ovary contains the entire pool of primordial follicles from the time of 
birth. In recent years, the exact origin of these follicles and their functions during 
reproductive life has been established. At birth, the ovary is filled with immature germ 
cells that later differentiate into mature germ cells or oocytes. The oocytes mature in the 
presence of supporting GCs as distinct follicles surrounded by a basement membrane 
(Figure 1.3). 
The process by which follicles develop and are selected for ovulation is referred 
to as folliculogenesis. Folliculogenesis has three main stages: the formation of the 
primordial follicles, the recruitment of the primordial follicles into the pool of growing 
follicles, and lastly ovulation of the mature follicle with formation of the 
steroidogenically active corpus luteum post-ovulation (Edson et al., 2009). The formation 
of the primordial follicles occurs at approximately gestational wk 18 to 22 (Wallace & 
Kelsey, 2010) in humans and E12.5 in mice, following the stimulation of the pre-GCs by 
inhibins to surround a single oocyte (McLaren, 1991; Chen et al., 2012; Knight et al., 
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2012). The next stage of folliculogenesis requires the transcription factor FOXL2 and the 
Epidermal growth factor receptor (EGFR) to facilitate the transition and recruitment of 
the primordial follicles to primary, secondary/pre-antral, antral and preovulatory follicles 
(Jamnongjit et al., 2005). The transition between primordial follicles and primary 
follicles is marked by an increase in the cell division of GCs surrounding the oocyte. The 
GCs continue proliferating to form a double layer, forming two populations: the cortical 
or cumulus cells that immediately surround the oocyte and the mural cells that line the 
follicle wall (Figure 1.3). A single layer of TCs is then recruited to surround the outside 
of the follicle marking the transition to the secondary or pre-antral phase. Prior to the 
antral stage, follicle growth occurs independent of gonadotropins. The formation of the 
antrum, a fluid-filled cavity between the oocyte and the surrounding GCs and the 
differentiation of the TCs into two distinct layers, the theca interna and theca externa, 
marks the formation of the antral follicle. The presence of antral follicles in the ovary 
marks the onset of puberty and the start of follicle regulation by gonadotropins. 
Prior to sexual maturity and puberty, primordial follicles located in the medulla of 
the ovary become activated as the first wave of follicles. They were initially believed to 
not contribute to fertility (Peters, 1969). In 2013, Zheng et al. determined that although 
this early wave of follicles is present primarily during non-reproductive stages, they do 
indeed contribute to fertility in the beginning of puberty and early sexual maturity. Since 
this discovery, it has been established that along with their role in fertility, it is likely that 
in the pre-pubertal ovary, these medullary follicles help to establish the hypothalamic-






Figure 1.3 Ovarian folliculogenesis 
 
Folliculogenesis can be separated into three main stages: primordial follicle formation, a 
pool of growing follicles, and lastly ovulation of the mature follicle and formation of the 
corpus luteum. The GCs continue proliferating to form a double layer, forming two 
populations: the cortical or cumulus population and the mural population Thecal cells are 
then recruited to surround the outside of the follicle marking the transition to the 
secondary or pre-antral phase. Finally, the formation of the antrum, the theca interna and 
theca externa, marks the formation of the antral follicle. This is followed by ovulation of 
the oocyte and cumulus GC from the mature, antral follicle, which then stimulates the 
formation of the corpus luteum from the remaining mural GC (Used with permission 






The process of follicle recruitment has been described in two distinct follicle waves. 
In 1992, Hirshfield was the first to describe a heterogeneous population of primordial 
follicles. By observing cell proliferation, it was determined that two distinct populations 
of follicular cells were present; the original population in the medulla, which began to 
grow first, and then another population that formed at a later stage in the cortex. These 
finding were further supported by continuing to look at ovarian cell proliferation in rats 
during the embryonic period through to several weeks post delivery, where it was 
confirmed that indeed the pool of follicles that is present at birth, is actually a 
heterogeneous population with two distinct origins (Hirshfield & DeSanti 1995). This 
work has been expanded with the advent of new technologies to further determine the 
origins of the GCs and the follicles in which they are incorporated. One study that added 
to what was previously known looked at tracing Foxl2-expressing cells. In this study, it 
was observed that not only are there two distinct follicle populations, a medullary and a 
cortical, but the pre-granulosa cells of these follicles arise from different populations of 
surface epithelium of the ovary (Mork et al. 2012). It was also suggested that the first or 
medullary wave of follicles is anovulatory and that both waves may be unique in their 
morphology, development and gene expression patterns (Mork et al. 2012). A follow up 
to this study was done by Zheng et al. (2014) to look at these possible developmental and 
physiological differences between the two waves of primordial follicles. Again Foxl2-
labeled cells were utilized as well as Spermatogenesis and oogenesis-specific basic helix-
loop-helix 1 (Sohlh1)-labeled cells to track each wave of follicles through fetal, 
adolescent and adult life. It was determined using these models that the first wave of 
follicles that are located in the medulla remain in the ovaries of mice from birth to 
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approximately 3 months where they play a role in the onset of puberty, as well as to early 
adulthood fertility, indicating the previous theory for their anovulatory status was not 
correct (Hirshfield 1992). This wave of follicles is gradually replaced by a second wave 
of follicles formed from a different population of surface epithelial cells and localized in 
the ovarian cortex. In female mice, from 3 months of age to the end of reproductive 
potential, this second wave acts as the primary source of ovulated follicles once the first 
wave has been replaced (Zheng et al. 2014). 
1.2.2 Puberty and the establishment of reproductive cyclicity 
	  
The normal maturation process for ovarian follicles during the reproductive cycle 
is regulated primarily by endocrine factors, but also by paracrine signals between the  
oocyte, the GCs that surround the oocyte, and the TCs that surround the basement 
membrane of each growing follicle (Edson et al., 2009; McGee & Hsueh, 2000). Steroid 
hormones are important for both normal ovarian function and the  
development of secondary sex characteristics in females. Steroid hormone production is 
regulated by the negative feedback loop of the hypothalamic-pituitary-gonadal (HPG) 
axis (Edson et al., 2009; Vadakkadath et al., 2005). The hypothalamus secretes 
Gonadotropin-Releasing Hormone (GnRH), to act on the gonadotrope cells in the anterior 
pituitary gland, stimulating the secretion of Luteinizing Hormone (LH) and Follicle 
Stimulating Hormone (FSH). Both hormones are important for both follicular 
development and ovulation following the start of puberty in mammals (Figure 1.4). It is 
after the pubertal transition that the coordinated release of LH and FSH initiate the 
maturation of a subset of follicles according to a species-specific estrous cycle. It is at 





Figure 1.4 The hypothalamic-pituitary-gonadal axis 
 
Steroid hormone production in the ovary is regulated by the hypothalamic-pituitary- 
gonadal (HPG) axis, which is controlled by a negative feedback loop. Gonadotropin- 
Releasing Hormone (GnRH) is secreted by the hypothalamus, which subsequently acts on 
the anterior pituitary gland to stimulate the secretion of Luteinizing Hormone (LH) and 
Follicle Stimulating Hormone (FSH). These hormones stimulate the release of 17β- 
Estradiol from the gonad, which acts to block the release of GnRH, LH and FSH from the 








(LHR) and FSH (FSHR), respectively (Adashi, 1994). FSH binding to its cognate 
receptor promotes GCs to proliferate and express cytochrome P450, family 19, subfamily 
a, polypeptide 1 (CYP19A, aromatase) and 17β-hydroxysteroid dehydrogenase (17β-
HSD), the enzymes necessary for the production of 17β- estradiol (E2) from androgenic 
metabolites produced by the TCs (Vadakkadath et al., 2005). Ligand activation of the 
growth factor receptor EGFR acts in GCs together with FSH and LH to facilitate this  
normal progression of ovarian steroidogenesis (Jamnongjit, et al., 2005). Upon the 
maturation of the antral follicles, FSH initiates their recruitment for eventual ovulation, 
and a surge of LH from the anterior pituitary results in the rupture of the follicle and the 
expulsion of the oocyte into the Fallopian tubes. To supplement its role in ovulation, FSH 
also prevents GC apoptosis and follicular atresia from occurring prior to ovulation. The 
antral follicles that have matured, but are not selected for ovulation, will die by atresia 
due to low FSH levels following ovulation. Post-ovulation, LH is also responsible for the 
luteinization of the GCs and TCs resulting in the formation of the corpus luteum, a highly 
vascularized tissue that produces the sex hormone progesterone (P4; Edson et al., 2009). 
In the absence of successful fertilization of oocyte, the secretion of E2 and P4 from the 
GCs triggers a negative feedback response in the hypothalamus to suppress the release of 
GnRH, while inhibins, molecules from the TGFβ family, act on the anterior pituitary to 
suppress FSH (Knight et al., 2012). As E2 secretion declines, negative feedback inhibition 
is released and the follicle maturation cycle resumes according to the timelines of 
different species. The regulation of these gonadotropins and sex hormones is necessary 
for the normal development, recruitment and ovulation of follicles. 






Figure 1.5 The two-cell, two-gonadotropin theory of hormone production and 
regulation in follicles  
 
The normal development of follicles relies on proper paracrine function. LH stimulates 
the thecal cells to produce steroidogenic acute regulatory protein (StAR) to aid the 
transport of cholesterol. LH stimulates the thecal cells to produce three enzymes; 
cholesterol side-chain cleavage enzyme (CYP11A1), cytochrome P450 17A1 
(CYP17A1) and 3β-hydroxysteroid dehydrogenase (3β-HSD). Cholesterol is converted 
by CYP11A1 to pregnenolone, which is then converted by CYP17A1 to first, 17-
hydroxypregnenolone and then dehydroepiandrosterone (DHEA). 3β-HSD then converts 
DHEA to androstenedione, which diffuses from the TCs, across the basement membrane 
to the GCs. The GCs then use CYP19A to convert androstenedione to estrone, which is in 
turn converted to E2 by 17β-HSD. E2 is then released into the vasculature to provide 




The normal development of follicles relies on proper paracrine function supported 
by the somatic GCs and is known as the two-cell/two gonadotropin theory (Adashi, 
1994). The release of FSH from the pituitary promotes not only the production of E2 and 
P4 by the GCs, but also their proliferation. LH plays a role by stimulating the thecal cells 
to produce steroidogenic acute regulatory protein (StAR) to aid the transport of 
cholesterol. LH stimulates the thecal cells to produce three enzymes; cholesterol side-  
chain cleavage enzyme (CYP11A1), cytochrome P450 17A1 (CYP17A1) and 3β-
hydroxysteroid dehydrogenase (3β-HSD). Cholesterol is converted by CYP11A1 to  
pregnenolone, which is then converted by CYP17A1 to first, 17-hydroxypregnenolone 
and then dehydroepiandrosterone (DHEA). 3β-HSD then converts DHEA to 
androstenedione. This diffuses from the TCs, across the basement membrane to the GCs. 
The GCs then use CYP19A to convert androstenedione to estrone, which is in turn  
converted to E2 by 17β-HSD  (Figure 1.5; Adashi, 1994; Edson et al., 2009). Over time, 
the release of competent, mature follicles becomes less consistent and both the endocrine 
and paracrine functions of the ovary begin to decline becoming less efficient as 
production of FSH, LH and E2 decrease. The decrease in reproductive potential leads to 
the next stage of the ovarian life. 
1.2.3 The post-menopausal ovary 
 
The recruitment of follicles and ovulation is fairly constant in mammals from the 
onset of puberty until the pool of follicles is depleted. In humans, this timeframe of 
recruitment and ovulation begins with the onset of puberty and lasts for several decades 
after its initiation, whereas in mice it begins at 1.5-2 months of age and lasts until 
approximately 16 months of age (Biggers et al., 1962). Once the production of hormones 
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necessary for normal follicle recruitment decline, so does ovulation (Finn 2001), at which 
time atresia of follicles increases and there is a noticeable decrease in fertility until 
menopause, which signals the end of reproductive potential (Gougeon, 2004).  
1.3 Ovarian Tumourigenesis 
 
In the ovary, pathologists have observed tumours arising from all potential cell 
types- germ cells, supporting cells and epithelial cells- suggesting the normal program 
and functions of these cell types confer a degree of tumourigenic risk. Tumours arising 
from the GC population are grouped in the sex-cord stromal tumour (SCST) class of 
ovarian tumours. In the human population, GC tumours (GCTs) may appear in infants, 
girls, young women or post-menopausal women, with broad classification as juvenile-
type or adult-type tumours (Jamieson & Fuller, 2012). With the knowledge of the two 
distinct follicle waves, the etiology of GCTs can be explored by combining knowledge of 
unique GC developmental origins with molecular profiling. This is a logical strategy to 
subclassify tumours arising from the GC population, to improve our understanding of this 
ovarian tumour class and to pave the way for preventative strategies and better clinical 
management of the disease. 
 1.3.1 Granulosa cell tumours 
 
Granulosa cell tumours are the most common subtype of SCSTs accounting for 
approximately 70 % of SCST cases in the human population (Colombo et al., 2007). 
Historically, the GCT tumour class has been divided into 2 distinct subtypes, adult and 
juvenile, occurring their appearance at both ends of the reproductive spectrum. The more 
common subtype is adult GCTs (AGCTs); these appear in older women at the end of 
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their reproductive life (Bjorkholm & Silfversward, 1981). At the other end of the 
spectrum are juvenile GCTs (JGCTs), which appear in female newborns through 
adolescence (Young et al., 1984). The classification of the subtypes has, in the past, been 
based upon the age at diagnosis and tumour histology, but in recent years has moved 
towards using genetic and molecular characteristics to better identify the tumour 
subtypes. 
1.3.2 AGCT of the ovary 
 
The more common subtype of GCTs is adult (AGCTs) which occur in older 
women during peri- and post-menopausal phases and account for approximately 95 % of 
all GCTs (Bjorkholm & Silfversward, 1981). Clinically, AGCTs present with post-
menopausal bleeding or secondary amenorrhea in peri-menopausal women caused by 
increased E2 and inhibin α production by the tumour; however, serum E2 levels are not 
indicative of disease progression as they are variable in women of different age groups 
(Bjorkholm & Silfversward, 1981). In a recent study of AGCTs and their biochemical 
properties, Kitamura et al. (2017) established that of 30 tumours investigated by 
immunohistochemistry (IHC), almost all had positive CYP19a and inhibin α expression. 
Elevated serum inhibin α suppresses the production of FSH from the pituitary, which 
partially explains the irregularity or loss of cyclic menses in peri-menopausal women 
with AGCT (Kitamura et al. 2017). 
The morphology of AGCTs has allowed pathologists to describe the tumours in 
several different terms, including insular, macrofollicular, microfollicular, diffuse and 
trabecular (Lloyd, 2010). These classifications do not correspond to clinical setting and 
cannot be used for diagnosis and prognosis (Kitamura et al., 2017). In recent years, a 
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recurrent, somatic, missense c.402C>G mutation in the FOXL2 gene which results in a 
change to tryptophan from a highly conserved cysteine (p.C134W) residue in the FOXL2 
protein was discovered by whole-transcriptome sequencing in 4 human AGCTs and 
subsequently confirmed in 86 AGCTs that were examined for this specific variant (Shah 
et al., 2009; Schrader et al. 2009). DNA sequencing and mutation analysis results from 
only 4 human AGCTs was possible due to the overall genomic stability of this tumour 
class (Shah et al., 2009). This c.402C>G mutation is heterozygous in almost all AGCTs, 
and unlike loss of function mutations in the FOXL2 gene which cause BPES, the 
functional effect of this mutation is presumably oncogenic (Fleming et al., 2010; 
Jamieson et al., 2010). Expression of the FOXL2 mutant gene and FOXL2 protein 
localization is generally unaffected in AGCTs (Schrader et al. 2009). This molecular 
finding was the first report for a consistent molecular feature in the AGCT category that 
has been quickly adopted as a molecular diagnostic test (Schrader et al. 2009).  
 Another important tool for the investigation of AGCTs is the KGN cell line. The 
KGN cell line is an immortalized, AGCT-like cell line that was developed from a tissue 
sample taken from an invasive, recurrent GC carcinoma of a 73-year old woman (Nishi et 
al., 2001). After the discovery and confirmation that the somatic c.402C>G mutation in 
the FOXL2 transcription factor gene was reproducibly characteristic of the AGCT 
subtype, the KGN cell line was investigated for the presence of the mutation. It has been 
reported that the c.402C>G FOXL2 mutation is heterozygous in the KGN line by 
sequencing the genomic DNA (Benayoun et al., 2010). For comparison to KGN, the 
same group investigated multiple non-ovarian and ovarian cancer cell lines of epithelial 
and sex cord-stromal origin, none of which harbored the mutation, supporting the specific 
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nature and potential diagnostic value of the FOXL2 mutation for AGCT. The presence of 
the somatic FOXL2 mutation, as well as the age of the woman from which the tissue for 
the cell line was obtained, has led several research groups to use the KGN line as a 
representative model for AGCT subtype-specific investigations (Benayoun et al, 2010; 
Fleming et al., 2010). 
1.3.3 JGCT of the ovary 
	  
Juvenile GCTs (JGCTs) occur most often in newborns through adolescence, with 
the mean age at diagnosis being 13 yrs of age (Young et al., 1984; Karalök et al. 2015).  
Clinically, patients often present with pain and distension in the abdomen, including 
abdominal bloating which is accompanied by premature menstruation due to their highly 
steroidogenic nature and the increased E2 and inhibin α production by the tumour (Young 
et al., 1984). When a physical examination is performed, many patients present with a 
palpable mass (Karalök et al. 2015).	  
The mechanism of initiation of JGCTs is unknown due in part to the rare nature of 
these tumours with incidence rates being only approximately 5 % of all GCTs. The 
occurrence of JGCTs at early time-points on the reproductive spectrum may support the 
hypothesis that they arise due to an underlying but unknown genetic risk factor, rather 
than the acquisition of somatic mutations as for AGCTs. The report by Shah et al. (2009) 
was also the first suggestion for a distinct molecular etiology for JGCTs vs. AGCTs due 
to the absence of the c.402C>G somatic FOXL2 mutation in the majority of JGCTs 
examined (Jamieson et al., 2010; Al-Agha et al., 2011). Clues to the mechanism for the 
development of JGCTs is currently lacking. 
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With the FOXL2 transcription factor being intimately involved in ovarian 
development and GC specification, the status of FOXL2 transcript or protein expression 
has been an area of study for JGCT etiology. Quantitative gene expression analysis 
showed detectable FOXL2 transcript in 3 JGCT samples, with expression levels at a 
similar order of magnitude and degree of variability as for AGCT samples (Jamieson et 
al., 2010). IHC of JGCT tissues has also been performed to determine the FOXL2 
expression status in these pediatric neoplasms. Kalfa et al. (2007) examined a cohort of 
26 JGCT specimens for FOXL2 expression relative to normal ovary controls. This group 
reported reduced FOXL2 protein expression in 53 % of the JGCT cases examined (n = 
14), with no FOXL2 protein expression detected in 38 % of this subset (n = 10). The 
authors provided a complete clinical history of the patients, leading to a significant 
correlation of advanced tumour staging with reduced or absent expression of FOXL2 
(Kalfa et al., 2007). The authors speculate that alterations of FOXL2 expression are an 
acquired feature in this subset of JGCTs, as the contra-lateral ovary functions normally in 
these patients after surgical recovery and pubertal maturation. In those JGCT specimens 
identified as having normal FOXL2 expression by IHC, the authors noted that FOXL2 
was not abnormally sequestered in the cytoplasm (Kalfa et al., 2007). Based on this 
limited number of studies, an examination of FOXL2 gene or protein expression in JGCT 
specimens has not achieved the same status as for AGTs, where the c.402C>G somatic 
FOXL2 mutation is considered a molecular diagnostic feature (Table 1.2). To identify 
molecular classifiers unique to the JGCT class, immortalized human GCT cell lines and a 
mouse strain that exhibits spontaneous, juvenile-onset GC tumours are models for 
continued exploration and discovery.  
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1.3.3.1 COV434 human GCT cell line 
 
 The COV434 cell line is an immortalized, human derived cell line that was isolated 
from a primary human GCT of a 27-year-old woman (Van Den Berg-Bakker et al., 1993; 
Zhang et al., 2000). It was initially described with 7 other ovarian cancer cell lines from 
serous, mucinous and endometrioid carcinomas and was determined to be a “borderline” 
malignant tumour by investigation of the growth characteristics and the cytogenetics, 
specifically trisomy on Chr 5 and structural rearrangement of Chr 22 (Van Den Berg-
Bakker et al., 1993). The cultured COV434 cells formed small aggregates, which were 
very similar to that of GCs aspirated from IVF patients indicating a cellular morphology 
of GCs (Zhang et al., 2000). In addition to cellular morphology, one of the properties 
investigated was the status of FSHR. The COV434 cells were not found to have any 
mutation in the FSHR gene by reverse transcriptase polymerase chain reaction (RT-PCR) 
and the receptors were found to be intact and functioning normally (Fuller et al., 1998). 
Another indication of GC origin is the ability to stimulate the cells with FSH to promote 
proliferation and secretion of E2, suggesting the presence and proper functioning of 
FSHR in this cell line. In addition, the intercellular connections made between GCs and 
the cumulus oophorus were examined. It was determined that COV434 cells make 
intercellular connections with the cumulus oophorus, indicating the retention of some 
normal GC phenotypes; however, the connections are only made when an intact oocyte is 
present (Zhang et al., 2000).  
 Following the detection and strong association of the p.C134W mutation in the 
FOXL2 gene in AGCTs and the KGN cell line, similar investigations followed for the 
JGCT-like COV434 cell line. The genomic sequence of the the FOXL2 gene in COV434  
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Table 1.2 Comparison of adult type and juvenile type GCTs in humans.  
	  
Characteristics Adult-type Juvenile-type 
Frequency of GCTs in women ~ 95 % ~ 5 % 
Onset Increases risk at end of reproductive cycle 
Early onset (pediatric) – infant 
to < 20 years 
FOXL2 status FOXL2 402 C>G mutation (Shah et al. 2009) Wildtype FOXL2 allele 
Etiology Somatic mutation deregulates GC differentiation 
Proposed germline etiology 



















cells has been examined and it was determined that wildtype FOXL2 is present in this cell 
line (Fleming et al., 2010). Quantitative gene expression analyses have also been quite 
consistent, indicating very low expression levels of the FOXL2 transcript in COV434  
cells relative to the KGN cell line, primary JGCT samples or primary AGCT samples 
(Fleming et al., 2010; Jamieson et al., 2010; Rosario et al., 2013). Although examples of 
FOXL2 protein staining are not generally presented for COV434 cells in these 
publications, Jamieson et al. (2010) reported in their publication that no protein was 
detected by IHC methods. Much of the reported data on the COV434 cell line agrees with 
findings for primary JGCTs, leading to its continued use as a representative cell line for 
JGCTs in general, and perhaps representing a more advanced and aggressive JGCT stage 
based on reduced FOXL2 expression (Kalfa et al., 2007). 
 Since its early development (Van Den Berg-Bakker et al., 1993) and subsequent 
characterization many years later (Zhang et al., 2000), COV434 has been used by many 
groups as a juvenile-type GCT model, however, aside from the work done surrounding 
the somatic FOXL2 mutation done after its discovery in adult-type GCTs in 2009 (Shah 
et al., Jamieson et al., 2010b; Rosario et al., 2013), not much has been done to further 
investigate the properties which would confirm its origin. COV434 continues to be the 
accepted cellular model for use in exploring human GCs (Jamieson & Fuller, 2015; 
Pastuschek et al. 2015; Lunger et al. 2016) and will be considered as such for the purpose 
of this thesis and an investigation of juvenile GCT molecular properties as compared to 
an established mouse model early-onset GCT. Table 1.3 shows a comparison of the status 





Table 1.3 Comparison of KGN, COV434 cell lines and the SWR mouse model 
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1.3.3.2 SWR mouse model for early-onset GCT 
 
Mice have proven to be an exceptional model for studying many human 
conditions due to their genetic and physiological similarities, in addition to their short 
gestational period. The SWR inbred mouse strain is a defined model for spontaneous, 
juvenile-onset GC tumourigenesis (Beamer et al., 1985). This model has been described 
as a means to understand the genetic and endocrine triggers for early onset GC tumours 
(Beamer et al., 1985). In SWR female mice, a restricted window for GCT initiation 
coincides with the pubertal transition at approximately 3 to 4 wks of age (Tennent et al., 
1990). Tumour-bearing females may have unilateral or bilateral masses that are 
macroscopically visible by 8 wks of age (Beamer et al., 1985; Tennent et al., 1990). If no 
GC tumours develop within this period, the mouse will remain unaffected and fertility 
will be normal over the course of the reproductive lifespan. (Figure 1.6, Figure 1.7) 
 The GCTs that arise in SWR female mice are hormone-dependent, with a 
requirement for the endocrine environment of puberty to trigger tumour initiation. The 
importance of steroids and the HPG axis has been demonstrated by the implantation of 
genetically susceptible, pre-pubertal SWR ovaries into immunocompromised mice with 
no sex steroid production (scid/scid; hpg/hpg), to avoid graft rejection and test the 
influence of the endocrine environment on GC tumour initiation. The outcome was 
complete suppression of GCT initiation in an environment devoid of gonadotropins and 
sex steroids, suggesting that an intact HPG axis is necessary for tumour formation 
(Beamer et al., 1993). By treating the scid/scid;hpg/hpg recipient with human chorionic 
gonadotropin (hCG) to mimic the effects of LH, or with direct androgenic metabolites 
such as DHEA and testosterone, GC tumour initiation was rescued, indicating the 
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importance of androgenic stimulation to GC tumourigenesis in this model (Beamer et al., 
1988a; Tennent et al., 1993; Dorward et al., 2007). 
In SWR female mice, the trait of GCT susceptibility is heritable but trait 
penetrance is incomplete, ranging from < 1 % to > 25 %, depending on the endocrine 
environment and the genetic background (Beamer et al., 1985). For example, treatment of 
pubertal SWR female mice with exogenous androgens through diet supplementation or 
implants (slow release subcutaneous capsules) both act to increase tumour penetrance 
from <1 % to ≥ 25 % (Beamer et al., 1988b). Another strategy to overcome low trait 
penetrance without manipulation of the steroid environment came to be realized through 
mapping crosses designed to identify the genes responsible for GC tumour susceptibility. 
At least 3 discrete Granulosa cell tumour (Gct) susceptibility loci have been mapped to 
high resolution in the SWR strain: Gct1 located on Chr 4 (Beamer et al., 1988b; Beamer 
et al., 1998a; Dorward et al., 2005; Dorward et al., 2013; Smith et al., 2013) and Gct4 
and Gct6 located on Chr X (Beamer et al., 1998b; Dorward et al., 2003; Dorward et al., 
2013). Gct1 has been resolved to 1.65 mega bases (Mb; Beamer et al., 1988b; Dorward et 
al., 2013; Smith et al., 2013). This locus has been reported by mapping to be fundamental 
for tumour initiation with SWR contributing the susceptibility alleles (Gct1SW). Gct1SW 
behaves like an oncogene, since one copy is sufficient to confer GC tumour 
susceptibility, but two copies render GCT initiation more probable, but with the same 
pubertal timing (Beamer et al., 1988a). Gct4 and Gct6 are discrete loci on Chr X, over 35 
Mb apart in the equivalent segment of the long arm of human Chr X (Xq); (Dorward et 
al., 2003). The Gct6 locus was mapped as a GC tumour suppressor allele, although the 
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Figure 1.6 Histology of normal whole ovaries (A) and granulosa cell tumours (B) 
from SWR mice 
 
Normal whole, ovaries and sections of GCTs from SWR mice were fixed, stained with 
Hematoxylin and Eosin (H & E) and imaged at 20X. In A, you can see the follicles and 
normal cellular organization of the ovary. Arrows represent follicles in different stages 
and the GCs surrounding the oocyte. In B, the homogeneous cellular makeup of the 



























Figure 1.7 Gross GCT specimen from SWR mouse. 
 
A GCT extracted from a SWR background mouse. This tumour was a unilateral solid 







Dorward et al., 2013). The Gct4 locus is reported to be a strong modifier of GC tumour 
susceptibility; a likely candidate for the identity of Gct4 is the Androgen receptor gene 
(Ar) due to the role of androgens in GCT initiation and its location within the Gct4 
loci (Dorward et al., 2003). The homozygous congenic strain, SWR.CAST-X1, harbours 
a uniques Gct4 locus to render females more susceptible to spontaneous GC tumour 
development (~ 20 %) without endocrine manipulation by diet or surgical implants 
(Dorward et al., 2013). Similar GC tumour penetrance is also observed in F1 generation 
daughters obtained by crossing SWR dams and SWR.CAST-X1 sires, due to a strong 
paternal effect at Gct4 (Dorward et al., 2013). Developing a higher penetrance model 
allows investigation of multiple spontaneous GCTs where the biology of tumour 
initiation can be examined without the influence of external hormones. Interestingly, the 
mapped Gct loci did not implicate variation in the Foxl2 gene as a heritable susceptibility 
factor. An investigation of the Foxl2 gene sequence in SWR strain genomic DNA and 
cDNA generated from GCTS verified the expected reference genomic sequence with no 
evidence of somatic mutation in Foxl2 cDNA collected from GCTs (Smith et al., 
unpublished). Likewise, it has been noted that BPES patients with heritable mutations in 
FOXL2 do not exhibit increased susceptibility to GC tumourigenesis, suggesting other 
loci have greater influence (Kalfa et al., 2007). 
Many properties of the SWR mouse GCT model are similar to the JGCT class of 
human tumours. For example, established GCTs of SWR female mice are highly 
steroidogenic, producing high levels of both E2 and inhibins similar to human GCTs 
(Beamer et al., 1988a). In addition to increased production of E2, the mouse tumours also 
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result in decreased production of GnRH, FSH and LH by the HPG axis, as well as lower 
than normal levels of P4, T and dihydrotestosterone (DHT) in serum (Beamer, 1986). 
This is due to a normal suppression of the HPG axis by the increased E2 production 
(Figure 1.3). The early window of GCT initiation in SWR female mice also shows 
similarities with pediatric JGCT onset and points to the development of the tumours from 
the first wave of ovarian follicles (Zheng et al. 2014). The overall parallels with the 
human JGCT condition make this model appropriate for investigating pathways of JGCT 
tumourigenesis and its potential genetic contributions. 
 1.4 Experimental Rationale 
	  
As an experimental model of juvenile-onset GC tumourigenesis, the SWR inbred 
mouse strain provides a unique opportunity to investigate the genetics, endocrinology and 
tumour biology of JGCTs. The focus of this thesis investigation is the protein expression 
profile of normal mouse ovaries collected from the SWR.CAST-X1 congenic strain, vs. 
genetically-matched, spontaneous GCTs collected at 6-8 wks of age following tumour 
initiation at puberty. Included in the protein profile are transcription factors, enzymes, 
and receptors known to be expressed in the GC populations (Egfr, Esr2, Cyp19a, Fshr) 
and proteins known to play a role in gonad specification, transdifferentiation and/or GC 
tumourigenesis (Foxl2, Sox9). In addition to a comparison of the normal ovaries vs. overt 
GC tumours, protein lysates collected from the COV434 JGCT-like cell line will be 
compared to the mouse GCTs, to identify any common features, in the search for a 
biomarker of JGCT identity. 
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1. Juvenile-onset GCT specimens collected from SWR female mice < 8 wks of age 
are proliferative, benign tumours that will retain the expression profile of age-
matched normal ovaries for proteins of importance to ovarian physiology: Egfr, 
Fshr, Cyp19a and Esr2. 
2. GCT initiation in female SWR mice is an abnormal response to the normal 
endocrine stimulation of puberty, involving changes in the protein expression 
profile of the gonad specification factors Foxl2 and Sox9. 
3. Juvenile-onset GCT specimens collected from SWR female mice will have 
similar protein expression profiles to the COV434 cell line that is classified as a 
human JGCT model. 
1.5.2 Research Objectives 
	  
1) Using an immunoblotting technique, I will compare protein expression 
profiles for 6 fertility or gonad-specification proteins between normal ovaries 
and spontaneous, primary GC tumour samples collected from age-matched 
SWR-derived congenic female mice.  
2) Using an immunoblotting technique, I will compare protein expression 
profiles for 6 fertility or gonad-specification proteins between spontaneous, 
primary GC tumour samples collected from SWR-derived congenic female 
mice and the COV434 juvenile-type GC tumour cell line. 
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2.0 Materials and Methods 
2.1 Animal Husbandry and Protocol Approvals 
	  
Mice were housed in the central animal care facility of the Health Sciences Centre 
at Memorial University of Newfoundland. The Institutional Animal Care Committee, in 
accordance with Canadian Council on Animal Care guidelines, approved all animal care 
protocols (14-01-AD, 14-04-AD).  Mice were given Laboratory (autoclavable) Rodent 
Diet 5010 chow (27.5% protein, 13.5% fat, 59% carbohydrate; LabDiet Co., St.Louis, 
MO) with sterile water ad libitum, and were housed under a 12:12 hour (h) light/dark 
cycle.  Mice were weaned at 20-23 days (d) of age and housed in groups of 2 to 5 animals 
per 27.94 cm (L) x 17.78 cm (W) x 12.7 cm (Ht) rodent cages in an individually 
ventilated caging system (Tecniplast, West Chester, PA) containing Bed-O-Cobs® corn-
cob bedding material (The Andersons, Maumee, OH) with additional housing and 
bedding enrichment. 	  
2.2 Tissue Sample Collection 
	  
	   Homozygous	  female mice of the SWR-derived congenic strain SWR.CAST-X1, 
or F1 female offspring from (SWR x SWR.CAST-X1) breeding pairs were used in this 
experiment given their heritable tendency for spontaneous GCT initiation at puberty 
(Tennent, Shultz, Sundberg, & Beamer, 1990). Female mice were euthanized by exposure 
to carbon dioxide (CO2) gas at 6 - 8 wks of age for inspection of the peritoneal cavity and 
the presence of unilateral or bilateral GCTs. Normal, whole ovaries were extracted and 
pooled from a single female for protein lysate preparation. When a unilateral or bilateral 
GCT was observed, the tumour was extracted and pieces of the tumour cleaned from as 
much blood as possible in a dish of sterile saline (0.85 % NaCl). GCT tissue fragments of 
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approximately 5-7 mm3 were processed for protein lysate preparation. Male mice of the 
SWR/Bm and C57B6 backgrounds were also harvested to extract prostate and testis 
tissue for immunoblotting and immunohistochemical analysis as control tissues for the 
Sox9 protein. To facilitate labeling, all tissue sample lysates were identified with a 
labeling system that used a letter for tissue type and a unique number for independent 
specimens. For example, N1 represents the sample collected for normal, pooled ovaries 
from a single unaffected female, whereas T1 represents a tumour fragment from a 
unilateral tumour from a single affected female, or T1A and T1B for individual fragments 
from bilateral tumours from a single affected female. Prostate tissue was labeled P1. 
The protein lysates for normal ovaries, GCT tissue samples and prostate were 
prepared in Radioimmunoprecipitation assay (RIPA) lysis buffer comprised of: deionized 
water, 1 x Protease Inhibitor Solution (Roche, Mississauga ON), 0.05 M Tris-
Hydrochloric Acid (HCl) pH 7.4 (Life Technologies, Carlsbad, CA), 0.005 M 
ethylenediaminetetraacetic acid (EDTA), 0.05 M Sodium Fluoride (VWR International, 
Radnor, PA), 1 x Dulbecco’s Phosphate Buffered Saline (PBS; Life Technologies, 
Carlsbad, CA), 0.1 % Sodium Dodecyl Sulfate (SDS; ThermoFisher Scientific, Waltham, 
MA), 1 % TritonX 100, 0.5 % Deoxycholate, 0.05 M β- Glycerophosphate, 0.001 M 
Sodium Orthovanadate, and 0.125 ng/mL phenylmethanesulfonyl fluoride (PMSF) all 
purchased from Sigma-Aldrich, St. Louis, MO unless otherwise stated. A pair of normal 
ovaries (< 1 g) was lysed in 50 µl of RIPA buffer, while GCT fragments and prostate (~ 1 
g) were lysed in 100 µl. Samples were homogenized in buffer using a Pellet Pestles 
Cordless Motor (Sigma-Aldrich, St. Louis, MO) and Kontes ® Pellet Pestle ® Grinders 
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(Kimble Chase, Vineland, NJ). Once the tissue was homogenized, the pestle was rinsed 
with 50 or 100 µl of RIPA lysis buffer (depending on the amount of tissue).  
Both homogenate and rinse were combined to compose the final tissue sample lysate. The 
sample lysates were centrifuged for 10 min at a speed of 21,000 x g at 4 °C (Thermo IEC 
Micromax Centrifuge) and the supernatant transferred to a fresh 1.5 mL microcentrifuge 
tube that was then stored at -80 °C until the time of protein assay. 
2.3 COV434 Cell Culture 
	  
	   COV434 cells were cultured as monolayers on cell culture plates (Greiner Bio-
One, Monroe NC) with DMEM plus 2 mM glutamine (Life Technologies, Carlsbad, CA), 
and supplemented additionally with 10 % Fetal Bovine Serum (FBS; ThermoFisher 
Scientific, Waltham, MA). The plates were incubated under standard culture conditions 
(37 °C, 5 % CO2; Forma™ Series II Water Jacket CO2 Incubator, ThermoFisher 
Scientific, Waltham, MA). Cells were passaged when they reached an estimated 
confluence of 80 % into new cell culture plates by washing cells 3 times with PBS before 
adding 1 mL of 0.25 % Trypsin-EDTA to detach the cells from the plate. The plate was 
incubated for 1-2 min to allow cells to detach before resuspending cells in DMEM media 
and distributing into new cell culture plates at a 1/3 dilution. 
2.4 COV434 Sample Collection 
	  
	   COV434 cells were plated in 6 well culture dishes at 1/3 density and grown to 80 
% confluence before protein lysate extraction from approximately 600,000 cells directly 
in the culture plate. The culture plates were placed on ice, the medium was aspirated and 
cells were washed 3 times per well with cold PBS (ThermoFisher Scientific, Waltham, 
MA). After washing, ice-cold RIPA lysis buffer (60 µl per 34.8 mm diameter well) was 
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added and the plate was tilted to fully cover the adherent cells. The plate was left on ice 
for 5 min after which it was tilted and left for an additional 5 min on ice. Each monolayer 
slurry was then scraped using a cell scraper (Corning, Corning, NY), combining the 
contents of 3 wells per 6-well plate into one 1.5 mL microcentrifuge tube as an 
independent COV434 sample. The tube was spun at 4 °C for 10 min at 21,000 x g 
(Thermo IEC Micromax Centrifuge) and the supernatant, approximately 180 µl, 
transferred to a fresh, labeled 1.5 mL microcentrifuge tube for storage at -80 °C until the 
time of protein assay. Using a similar labeling strategy as for normal ovaries and GCT 
samples, independently collected COV434 lysates were identified as C1, C2, C3, etc. 
2.5 Tissue Fixation 
2.5.1  Hematoxylin and Eosin Staining & Brightfield Imaging  
 
GCT tissue or normal ovaries collected at necropsy from genetically susceptible 
female mice were fixed in 4 % paraformaldehyde-PBS (pH 7.4) at room temperature 
overnight on a rotator and transferred to 70 % ethanol (EtOH) for Hematoxylin and Eosin 
(H&E) staining prior to paraffin embedding at the central Medical Education and 
Laboratory Support Services department (MELSS; Health Sciences Centre, Faculty of 
Medicine). After embedding, the tissues were sectioned at a thickness of 5 µm and 
mounted on glass slides for photomicroscopy. 	  
2.5.2 Tissue collection for immunohistochemistry (IHC) 
 
GCT tissue and normal ovaries from SWR strain background mice that were 
treated with DHEA capsules at 3 wks of age to induce tumour formation, were isolated 
and collected at necropsy at 8 wks of age (Smith  et al. 2013) from litter matched 
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genetically susceptible female mice and fixed in Bouin’s solution at room temperature for 
24 h on a rotator. Testis control tissue from wildtype male mice of the C57BL/6J 
background were isolated and collected at necropsy at 3.5 wks of age and fixed in 
Bouin’s solution at room temperature for 4 h on a rotator, Fixation occurred prior to 
paraffin embedding at the central MELSS (Health Sciences Centre, Faculty of Medicine). 
After embedding, the tissues were sectioned at a thickness of 5 µm and mounted on glass 
slides for IHC analysis (see section 2.10). 
2.6 Brightfield Imaging 
	  
	   H&E stained sections were imaged using a Leica DM-IRE2 inverted microscope 
(Leica Microsystems, Richmond Hill, ON) attached to a Retiga Exi CCD camera 
(QImaging, Burnaby, B.C.). Image capture was done using Openlab Image Analysis 
software (Version 5.5; Improvision, Inc., Lexington, MA) to observe the histology of 
normal SWR mouse ovaries and primary GCTs. SWR normal ovaries and primary GCTs 
were viewed and imaged at a magnification of 20 x and 40 x. Image contrast and 
brightness were adjusted uniformly to the images using Adobe Photoshop (San Jose, 
CA). 
2.7 BCA Protein Assay 
	  
Protein lysates were assayed using a BCA Protein Assay (ThermoFisher 
Scientific, Waltham, MA) to determine the protein concentration of each sample. Using 1 
mg/mL bovine serum albumin (BSA; ThermoFisher Scientific, Waltham, MA) as a stock 
protein standard, a 96 well plate (VWR International, Radnor, PA) was loaded in 
duplicate wells with a protein concentration gradient of 0, 2.5, 5, 10 and 20 µg BSA 
combined with 2 µl RIPA lysis buffer per well. Similarly, 2 µl of the experimental 
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samples were loaded into duplicate wells and the corresponding lysis buffer sample was 
loaded into separate wells, in duplicate, as a blank. Pierce™ BCA kit reagents 
(ThermoFisher Scientific, Waltham, MA) A and B were mixed at a 50:1 ratio, 
respectively to have sufficient volume to add 300 µl of the solution to each standard and 
experimental sample well. The plate was incubated at 37 °C for 30 min and read on a 
POLARStar OPTIMA Plate Reader (BMG LABTECH Inc., Cary, NC) at an absorbance 
of 562 nm. The optical density was compared against the standard protein concentration 
and a linear regression line was used to determine the amount of protein in unknown 
samples. The sample absorbance values were used to calculate the total protein 
concentration (µg/µl) of each sample. The concentration of protein (µg/ µl) was utilized 
to calculate the amount of sample (µl) that was required to obtain the desired protein 
amount (µg) for immunoblotting (10, 20 or 30 µg). 
2.8 Immunoblotting 
 
a. Electrophoretic separation of proteins 
Protein lysates made from normal ovary pairs, primary GCTs and the human 
COV434 cell line, were used to investigate the expression profile of 6 proteins; Cyp19a, 
Egfr, Esr2, Foxl2, Fshr, and Sox9. Once the desired volume of protein lysate was 
identified to achieve 10, 20 or 30 µg of total protein, it was added to 5X Sample Buffer [5 
x Sample Buffer Solution; 10 % glycerol, 5 % SDS, 50 mM TRIS-HCl pH 7.5 
(ThermoFisher Scientific, Waltham, MA) and 0.125 % bromophenol blue (VWR 
International, Radnor, PA) and 5 % β-mercaptoethanol (BME, ThermoFisher Scientific, 
Waltham, MA)]. To denature the protein, the samples were heated to 100 °C for 4 mins 
and centrifuged for 10 sec before loading. Acrylamide separation gel percentage was 
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determined based on the molecular weight of the particular protein of interest; proteins 
larger than 80 kDa, as predicted by the antibody product sheet, were separated on a 7.5 % 
gel, while proteins smaller than 80 kDa were separated on an 8.5 % gel. The molecular 
weight and percent gel for each protein of interest are listed in Table 2.1. Gel 
composition was made up as per Roberts et al. (1984).  
PageRuler Plus Protein Ladder (Invitrogen, Carlsbad CA) was loaded into the first 
well and all samples were loaded slowly to prevent mixing using gel loading tips 
(ThermoFisher Scientific, Waltham, MA). A prestained protein ladder was used to 
visualize the approximate size of the proteins of interest. By knowing the approximate 
size of each protein, we were able to match each band to the matching stained band of the 
appropriate size. All sample types - N, T and C - were analyzed together on a single blot 
with a particular antibody. Multiple blots of the same samples were analyzed to account 
for variability between immunoblotting assays. The gel was run at 15 mA until samples 
had completely passed through the stacking gel, after which they were run at 22 mA for  
approximately 1 h to achieve size separation. A Mini-PROTEAN Tetra Cell system (Bio-
Rad, Hercules, CA) was used for all protein electrophoresis. 
 
b. Protein transfer to a solid support membrane 
All proteins separated by electrophoresis were transferred to Polyvinylidene 
fluoride (PVDF) membrane (Millipore, Billerica, MA). The transfer sandwich was 
assembled as per manufacturer’s instructions (Bio-Rad, Hercules, CA). Protein transfer 
was performed at 100 V for 45 min in transfer buffer [25 mM TRIS base, 192 mM 
Glycine, 20 % Methanol (VWR International, Radnor, PA) chilled to 4 °C. Upon transfer 
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completion, the membranes were trimmed to the size of the gel, nicking the bottom right 
hand corner to maintain the correct orientation. The gel was checked for transfer 
efficiency by looking for the presence of bands from the pre-stained ladder standard on 
the gel prior to discarding to determine whether total protein transfer was accomplished.  
 
c. Immunoblotting 
After transfer, the PVDF membranes were quickly rinsed and placed in 10 mL of 
a blocking solution containing 5 % non-fat skim milk in TRIS buffered saline with 
Tween-20 [TBST; 0.01 M TRIS-HCl pH 7.4  (ThermoFisher Scientific, Waltham, MA 
and Invitrogen, Carlsbad, CA), 0.14 M NaCl and 0.1 % Tween-20 (VWR International, 
Radnor, PA)]. The blots were placed on a rocking platform at room temperature for at 
least 45 min. While the membranes were blocking, primary antibody dilutions were 
prepared. All primary antibodies were diluted in 6 mL of blocking solution. Working 
dilutions for each antibody are listed in Table 2.1. After blocking, the solution was 
discarded and the membranes were placed in primary antibody to incubate on the rocking 
platform at 4 °C overnight. 
 The membranes were then washed 5 times for 5 min each in TBST 
(approximately 10 mL per wash) on a rocking platform at room temperature. Following 
washing, the membranes were incubated with secondary antibody (Table 2.1) conjugated 
to horseradish peroxidase (HRP; Santa Cruz, Santa Cruz, CA) at a 1:5000 dilution in 
blocking solution for 1.5 hrs rocking at room temperature. After secondary antibody 
incubation, the membranes were transferred to clean containers and washed again in 
TBST, 5 times for 5 min. After washes, the membranes were placed in SuperSignal®  
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  Santa	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West Pico Chemiluminescent Substrate (ThermoFisher Scientific, Waltham, MA) with 
the A and B reagents mixed in a 1:1 ratio and incubated, with shaking, at room 
temperature for 5 min. The membranes were removed from the substrate, allowing any 
excess to drain, placed on a plastic backing, covered in plastic wrap (Kirkland Signature, 
Kirkland, WA), and placed in a x-ray cassette. In a dark room, protein bands were 
visualized by exposing CLINICSELECT Green X-ray film (Carestream Health, 
Rochester, NY) or Amersham Hyperfilm™ ECL film (GE Healthcare, Pittsburgh, PA) 
and developed (Mini Med Film Processor, AFP Imaging Corporation, Elmsford NY).  
The membranes were stripped to enable re-probing with an antibody to a 
housekeeping cellular protein as a loading control. Membranes were stripped (distilled 
water, 1% SDS, 20 mM TRIS-HCl pH 6.8 and 0.8 % BME) for 10 min in a shaking water 
bath at 50 °C. After incubation, the membranes were washed twice for 5 min each in 
TBST. The membranes were blocked and washed as previously described. Tubulin- α/β 
(Cell Signaling Technology, Danvers, MA) was used as a loading control for all proteins 
with the exception of Egfr, for which we used β-actin (Cell Signaling Technology, 
Danvers, MA) as a loading control. All tubulin or β-actin antibodies were diluted in 
blocking buffer and are listed in Table 2.1. The same procedure was followed for the 
loading control proteins, as with the proteins of interest, with the exception of using a 
mouse HRP-conjugated secondary antibody (Santa Cruz, Santa Cruz, CA) for β-actin. To 
account for variability between immunoblotting assays, all sample types, normal, whole 
ovary, GCT and COV434 lysates, were analyzed together on a single blot, allowing for 
multiple biological replicates to be analyzed relative to each other. For Cyp19a, Egfr, 
Esr1 and Sox9, a total of 6 biological replicates were analyzed. For Foxl2 and Fshr, 5 
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biological replicates were analyzed. Biological replicates were repeated 2 or 3 times to 
minimize technical variability between identical samples (Appendix B). An additional 
replicate of the Sox9 protein was completed using a monoclonal Sox9 antibody (Cell 
Signaling Technology, Danvers MA) to confirm prior immunoblotting results. Films 
were scanned in black and white at 600 dpi using a Canon MX450 series scanner. 
Saturation of the bands was determined by visual inspection, which is a limitation of this 
technique. Images were saved as JPEG files and analyzed in ImageJ 1.47v 




Bouin’s fixed tissues were embedded in paraffin, sectioned at a 5 µm thickness 
and mounted on VWR® Superfrost® Plus Micro Slides (VWR International, Radnor PA) 
at the central Medical Education and Laboratory Support Services (MELSS) department 
(Health Sciences Centre, Faculty of Medicine). Slides were held in a 45 °C drying oven 
overnight to ensure section adherence before processing. Normal female mouse ovaries, 
male mouse testes and mouse GCT samples were included in the immunohistochemistry 
(IHC) analysis. 
 To start, tissues adherent to glass slides were deparaffinized and hydrated by a 
manual processing strategy, as follows; xylene tanks (3 x 5 min) followed by 100 % 
ethanol tanks (2 x 10 min), 95 % ethanol tanks (2 x 10 min) and lastly into ddH2O (2 x 5 
min) each. After deparaffinization, 15 mL of concentrated Citrate buffer (Vector 
Laboratories, Burlingame CA) was added to 1.6 L of ddH2O in a pressure cooker to start 
antigen retrieval (Deni® model). The slides were immersed in diluted Citrate Buffer 
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solution (pH 6.0) and pressurized at the high temperature setting for 5 mins. After the 
cooker depressurized slowly, the slides were removed and washed in ddH2O (2 x 5 min). 
 The slides were subsequently placed in 3 % hydrogen peroxide (H2O2) for 10 min 
to quench the endogenous peroxidase activity, followed immediately by ddH2O twice for 
(2 x 5 min) and 1X TBST (1 x 5 min). The blocking serum was prepared by adding 6 
drops of stock goat anti-rabbit serum from the VECTASTAIN Elite ABC Reagent Kit 
(Vector Laboratories, Burlingame CA) to 20 mL of 1X TBST. Each slide was blotted 
with filter paper to remove excess TBST and tissue samples were outlined using an 
ImmEdgePen (Vector Laboratories, Burlingame CA) to Immunoglobulin G (IgG) control 
and primary antibody-treated sections. After tissue sections were isolated with a 
hydrophobic perimeter, slides were placed horizontally in a hydration container and 
spotted with blocking serum at room temperature for 60 min. During the blocking serum 
incubation, the primary antibodies were prepared on ice. A rabbit-derived monoclonal 
antibody for Sox9 protein (Cell Signaling Technology, Danvers MA), was prepared at a 
1:400 dilution in blocking serum with a respective rabbit IgG (negative control; Santa 
Cruz, Santa Cruz CA), prepared at an equivalent dilution in blocking serum to that of the 
Sox9 antibody. After 60 min of blocking, the slides were blotted to remove excess 
blocking serum and the slides were placed back into the hydration container. Tissues 
were immediately spotted with their respective IgG control and or Sox9 primary 
antibodies. Antibody incubations proceeded overnight at 4 °C.  
 The following day, the secondary biotinylated antibody reagent was prepared by 
adding 1 drop of the biotinylated antibody stock from the VECTASTAIN Elite ABC 
Reagent Kit to 10 mL freshly prepared blocking serum in TBST (3 drops per 10 mLs). 
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The ABC detection reagent was prepared in a separate tube by adding 2 drops of Reagent 
A to 5 mL of 1X TBST, inverting to mix and then adding 2 drops of Reagent B followed 
by mixing. The ABC Reagent solution was prepared at least 30 min prior to slide 
application, as recommended by the manufacturer’s instructions.  
Slides were blotted to remove the primary antibody and washed in tanks of fresh 
1X TBST (3 x 5 min). The slides were placed back into the hydration container and 
coated with the secondary antibody and left to incubate for 30 min at room temperature. 
Following the incubation, each slide was blotted and placed into fresh 1X TBST (3 x 5 
min). The slides were placed back into the hydration container and coated with the 
prepared ABC Reagent and incubated for 30 min at room temperature. During this 
incubation, the 3,3’-diaminobenzidine (DAB) Substrate was prepared by adding 2 drops 
of the DAB Chromogen concentrate to 2 mL of ImmPACT DAB Diluent and vortexing 
to mix (ImmPACT DAB; VECTASTAIN Elite ABC Reagent Kit, Vector Laboratories, 
Burlingame CA). This solution was protected from light to prevent activation prior to 
application.  
Following 30 min in the ABC reagent, the slides were blotted before placing them 
into fresh 1X TBST for 5 min and then dipping them quickly in ddH2O (5 dips). Slides 
were blotted once more, placed into the hydration container and the tissue sections 
spotted with DAB substrate. Slides were incubated with the DAB substrate for up to 25 
min or until colour was evident in the positive control testis tissues for Sox9 staining. 
Slides were blotted and placed in ddH2O for 5 min to remove excess DAB substrate. The 
tissues were then dehydrated by dipping the slides 20 times each in 95 % ethanol (x2 
tanks), 100 % ethanol (x2 tanks) and xylene (x2 tanks). Coverslips were added to each 
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slide using VectaMount Mounting Medium (Vector Laboratories, Burlingame CA), 
carefully so as not to introduce any air bubbles and the slides were cleaned with xylene 
soaked gauze. Slides were laid flat to dry and stored at 4 ° C prior to brightfield imaging 
and digital image capture. 
2.11 Statistics 
	  
	   Microsoft Excel (Microsoft, Redmond WA) was used to calculate the 
densitometric relative amount of proteins of interest to its respective loading control from 
the same transfer membrane. Once the ratios were determined, these normalized values 
were entered in GraphPad Prism (GraphPad Software, Inc., La Jolla CA) to perform one-
way ANOVA with Tukey’s Multiple Comparison Test to determine differences in the 
expression pattern between normal, mouse GCT or the human COV434 cell lysates. For 
this purpose, a p-value ≤ 0.05 was considered significant. 




GCTs appear in SWR-derived female mice with a tumour frequency of 
approximately 20 % in high penetrance crosses. In this study, a total of 288 females were 
examined from (SWR x SWR.CAST-X1) F1 generation matings at age 6 wks, with 32 
GCTs macroscopically identified (11.1 % frequency). GCTs for protein lysates were 
selected based on the presence of viable tissue (non-necrotic) and sufficient tissue 
availability after microdissection and rinsing away excess blood, in order to collect 6 
individual spontanteous GCTs for protein lysates (Appendix B). Although GCTs isolated 
from young SWR female mice and the COV434 cell line possess similar presentation 
features that support their exploration as JGCT model systems, this is the first time they 
have been directly compared for protein expression. A complement of six proteins 
influential for gonadal development and ovarian function - Cyp19a, Egfr, Esr1, Foxl2, 
Fshr and Sox9 – were examined by immunoblotting in normal, whole ovaries and 
spontaneous GCTs isolated from SWR-derived female mice, as well as the human JGCT-
like cell line COV434.  




The expression of Cyp19a enzyme was examined in normal whole mouse ovaries, 
age-matched mouse GCT specimens and COV434 whole cell lysates by immunoblotting, 
using a polyclonal antibody suited for cross-species protein detection.  A representative 
immunoblot exhibits a 58 kDa relative molecular weight (Mr) band for Cyp19a in all 
experimental samples, relative to an α/β Tubulin loading control (55 kDa) that was used 
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to normalize the expression for each individually loaded sample (Figure 3.1). A 
quantitative comparison of the normalized mean band density revealed no significant 
difference in the expression of Cyp19a between normal whole ovaries or GCTs or 
between normal whole ovaries or the COV434 cell line; however, the mean level of 
Cyp19a expression was approximately 4-fold higher in the COV434 cell line compared to 
GCTs having statistical significance with a p-value of 0.0254 (n= 6 per group). 
Fshr 
	  
	   Likewise, the expression of the gonadotropin receptor Fshr was examined 
between normal whole mouse ovaries collected from the SWR-derived female mice, 
independent mouse GCT specimens and COV434 whole cell lysates by immunoblotting, 
using a polyclonal antibody suited for cross-species protein detection. A representative 
immunoblot exhibits Fshr detection at a Mr of 76 kDa in all samples examined, using the 
loading control band for α/β Tubulin to normalize the expression for each individual 
sample (Figure 3.2). No significant differences in the expression of Fshr were found 
between the normalized band density of the three experimental groups (n = 5 per group), 
however there appeared to be slightly higher expression in the normal ovarian samples.  
Egfr 
	   	  
Egfr expression was examined in normal whole mouse ovaries, mouse GCT specimens 
and COV434 cell lysates by immunoblotting using a polyclonal antibody that has cross-
species reactivity. The Egfr banding pattern exhibited a Mr of 170 kDa, whereas the 








Figure 3.1 Quantitative representation and immunoblot analysis of Cyp19a 
Quantitative representation and immunoblot of Cyp19a expression in normal ovaries (N), 
JGCTs (T) and COV434 cell lysates (C) normalized to α/β Tubulin. [* represents 
statistical significance (p≤0.05)]. A quantity of 20 µg of protein was loaded in each lane. 









different exposure times, with the loading control β-actin used to normalize the relative 
expression for each individual sample. Egfr was significantly overexpressed in mouse 
GCTs, with a mean 10-fold increase when compared with the normal, whole ovary (p = 
<0.0001) and COV434 sample lysates (p = 0.0007). No difference was observed between 
normal, whole ovaries and the COV434 cell line. With equivalent protein loading, 
increased exposure time was required for Egfr band detection in the normal ovary and 
COV434 lysates and no significant difference was observed (Figure 3.4).  
Esr2 
	   	  
Esr2 expression was examined in normal whole ovaries, mouse GCT specimens and 
COV434 cell lysates by immunoblotting, using a polyclonal antibody with cross- species 
reactivity. Figure 3.5 shows a representative blot of Esr2 with the loading control α/β 
Tubulin used to normalize the relative expression for each individual sample. Esr2  
exhibited a Mr of 56 kDa, as per the expected molecular weight for Esr2. The quantitative 
densitometric analysis showed a 2-fold reduction in the expression of Esr2 expression 
between normal, whole ovary and GCT lysates (p = <0.0001), with a further 2-fold 
reduction between GCTs and COV434 lysates (p = <0.0001). A significant decrease was 
also observed between normal, whole ovary and COV434 lysates (p = <0.0001; n = 6). 
Foxl2 
	  
The presence of Foxl2 expression in normal whole ovaries, mouse GCT specimens and 
COV434 cell lysates was evaluated by immunoblotting using a polyclonal antibody 















Figure 3.2 Quantitative representation and immunoblot analysis of Fshr 
Quantitative representation and immunoblot of Fshr expression in normal ovaries (N), 
JGCTs (T) and COV434 cell lysates (C) normalized to α/β Tubulin. A quantity of 30 µg 






















Figure 3.3 Quantitative representation and immunoblot analysis of Egfr 
Quantitative representation and immunoblot of Egfr expression in normal ovaries (N), 
JGCTs (T) and COV434 cell lysates (C) normalized to β-actin. [* represents statistical 













Figure 3.4 Quantitative representation and immunoblot analysis of Egfr 
Quantitative representation and immunoblot of Egfr expression in normal ovaries (N), 
and COV434 cell lysates (C) with increased exposure time normalized to β-actin. JGCT 
(T) samples were not analyzed due to overexposure. A quantity of 30 µg of protein was 














Figure 3.5 Quantitative representation and immunoblot analysis of Esr2 
Quantitative representation and immunoblot of Esr2 expression in normal ovaries (N), 
JGCTs (T) and COV434 cell lysates (C) normalized to α/β Tubulin. [* represents 
statistical significance (p≤0.05)]. A quantity of 30 µg of protein was loaded in each lane. 












exhibited a Mr of 38 kDa as per the expected molecular weight for Foxl2. Figure 3.6 
shows a representative blot of Foxl2 with the loading control α/β Tubulin used to 
normalize the relative expression for each individual sample. Quantitative densitometric 
analysis showed no significant difference in the expression of Foxl2 was found between 
the three experimental groups (n = 5). 
Sox9 
	  
Sox9 expression was examined in normal whole ovaries, mouse GCT specimens and 
COV434 cell lysates by immunoblotting, using a polyclonal antibody with cross-species 
reactivity (H90, Santa Cruz Inc., Santa Cruz CA).	  Immunobloting revealed a band at a Mr 
of 65 kDa, whereas the predicted molecular weight for Sox9 is 56 kDa; however the same 
molecular weight band was detected in a positive tissue control lysate prepared from 
male mouse prostate gland suggesting a slight variation in size.  Figure 3.7A shows the 
representative blot of Sox9 with the loading control α/β Tubulin used to normalize the 
relative expression for each individual sample. Quantitative densitometric analysis of the 
mean band density indicated that Sox9 was expressed approximately 10-fold higher in the 
GCT samples when compared with the normal, whole ovaries (p = 0.0113; n = 6) and 
approximately 20-fold higher relative to the COV434 cell lysates (p = < 0.0001; n = 6). 
Unlike all the other proteins examined so far that have a predicted expression profile for 
female ovarian tissues, Sox9 is an important regulator of male gonad development and 
the high expression observed in mouse GCTs was unexpected. Therefore, this finding 








Figure 3.6 Quantitative representation and immunoblot analysis of Foxl2 
Quantitative representation and immunoblot of Foxl2 expression in normal ovaries (N), 
JGCTs (T) and COV434 cell lysates (C) normalized to α/β Tubulin. A quantity of 30 µg 







Figure 3.7 Quantitative representation and immunoblot analysis of Sox9 
Quantitative representation and immunoblot of Sox9 expression in normal ovaries (N), 
JGCTs (T) and COV434 cell lysates (C) normalized to α/β Tubulin (A & B), mouse 
prostate (A) and testis (B) for a relative comparison of intensity of expression. A 
polyclonal Ab (H90; A) and monoclonal Ab (D8G8H; B) confirmed expression. [* 
represents statistical significance (p≤0.05)]. A quantity of 30 µg of protein was loaded in 




Signaling Technology, Danvers MA) useful for immunoblotting and IHC between mouse 
and human tissues. 
Figure 3.7B shows the representative immunoblot for Sox9 expression in matched 
normal ovary and GCT lysates to those examined in Figure 3.7A, but using the  
monoclonal Sox9 antibody (n = 4). For these immunoblots, fresh lysates were prepared 
for the COV434 cell line (n = 4) and male mouse testis was used to prepare a positive 
tissue control for Sox9 expression for both immunoblotting and IHC. No significant 
difference was observed between the three groups however, this could be due to the small 
sample size and there is a trend for consistent expression in Figure 3.7A and 3.7B. In 
Figure 3.7B, the intensity of the GCT expression is less than in Figure 3.7A and Sox9 
expression is present in the normal ovaries. Sox9 was not detected in the COV434 cell 
line using either the polyclonal or the monoclonal antibody.  
3.2 Immunohistochemical Analysis 
	  
	   In Figure 3.8, the presence of Sox9 expression in normal whole ovaries (A) and 
testis control tissue (B) was evaluated by IHC. Figure 3.8A shows the normal whole 
ovaries with H and E staining at 5X magnification, the IgG antibody control stained 
tissue (inset), and the Sox9 stained tissue at 10X magnification and 20X magnification. 
Figure 3.8B shows the testis control tissue with H and E staining at 5X magnification, the 
IgG antibody control stained tissue (inset), and the Sox9 stained tissue at 10X 
magnification and 20X magnification. In the testis, a specific Sox9 staining is evident in 
the Sertoli cells, as expected. In the normal ovary sections, stromal cells, possibly thecal 
cells, of uncertain identity surrounding growing follicles show positive Sox9 staining, 













Figure 3.8 IHC of normal gonad condition 
IHC analysis of normal whole ovaries (A) and normal testis tissue (B) from mice. H&E 
staining is at a magnification of 5X (Scale bar = 100 µm). The inset shows IgG control 
staining at 10X magnification. Sox9 staining is shown at magnifications of 10X (Scale 





























Figure 3.9 IHC of JGCTs from SWR background mice 
IHC analysis of two unique JGCTs (A & B) from SWR background mice. H&E staining 
is at a magnification of 5X (Scale bar = 100 µm). The inset shows IgG control staining at 
10X magnification. Sox9 staining is shown at magnifications of 10X (Scale bar = 50 µm) 
and 20X (Scale bar = 20 µm), respectively. In B, for Sox9 staining at 20X, the inset 
shows an intact follicle in the GCT showing the same staining pattern as in Figure 3.8A. 








Figure 3.9 shows two unique GCT specimens with H and E staining at 5X 
magnification, the IgG antibody control stained tissue (inset), and the Sox9 stained tissue 
at 10X magnification and 20X magnification. Clusters of Sox9 positive cells are present  
in proliferative (non-necrotic) regions of both GCTs, although expression is not 
consistent throughout the tumour mass. The contribution of Sox9 expressing cells in the 
normal ovaries and the GCTs support the detection of a band following immunoblotting 


















	   GCTs can be classified as either adult or juvenile subtypes based on the age of 
onset and histology, affecting girls and women at both ends of the female reproductive 
spectrum. Although the adult subtype has been classified in humans by a consistent 
somatic mutation in the FOXL2 gene, as of yet, no altered gene or protein has been 
identified as a consistent molecular feature for the JGCT type (Shah et al. 2009). The 
COV434 cell line established from a human GCT retains features of normal GC but does 
not possess the AGCT-associated mutation in FOXL2, rendering it as a frequently used 
model for JGCT (Zhang et al., 2000). Early-onset GCTs appear in females of the SWR 
inbred strain driven by heritable susceptibility loci on Chr 4 and Chr X, as a model of 
JGCT development that is independent of Foxl2 genetic variation on mouse Chr 9 (Smith 
et al., unpublished). To compare these two JGCT model systems, I examined the 
expression of six essential proteins related to normal mammalian gonadal development 
and reproductive function: Cyp19a, Egfr, Esr2, Foxl2, Fshr and Sox9. Each protein 
examined was assessed by immunoblotting in individual mouse GC tumours compared to 
normal whole ovaries from female mice of the same young age and strain background, as 
well as lysates derived from the COV434 human cell line. Although GCs represent a 
major contributing cell type to the young ovary and the mouse GCTs, the sampling of 
whole mouse ovaries and GCTs to create mixed protein lysates is one limitation of this 
study due to the heterogeneity of cell types present. To address this limitation for Sox9 
specifically, IHC was performed for Sox9 expression in the normal mouse ovary and 
unique mouse GCTs, to identify the Sox9 expressing cells. Overall, the objective of this 
thesis was to determine how similar the protein profile is the normal mouse ovaries, 
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mouse GC tumours and the COV434 line to provide leads for proteins and genes that 
may be commonly expressed, as foundation for further translation of candidate proteins 
or gene expression as the mapped SWR Gct susceptibility loci are investigated in the 
human COV434 cell line for gene-coding or regulatory variants that trigger early onset 
tumourigenesis. 
4.1 SWR mouse strain GC tumours and the normal ovarian condition 
	  
Spontaneous GCTs are rare in the human condition, with JGCTs even more rare 
than AGCTs, making the determination of their unique etiology challenging (Young et 
al., 1984). If the SWR mouse model for spontaneous, early-onset GC tumours is a 
translational model for the human JGCT condition, there is a developmental window, a 
genetic susceptibility and an endocrine trigger that must all come together for GC 
tumours to initiate (Beamer et al., 1985, Tennent et al., 1990). The initiation of GC 
tumours during the brief developmental window in SWR female mice between the ages 
of 3 to 4 wks suggests an early alteration present from birth, with strong influence of 
heritable genetic factors influence the mouse model (Tennent et al., 1990). The normal 
ovary provides a baseline to compare the protein profile to individual GC tumours, being 
collected from genetically identical and age-matched mice; this is a more representative 
overview of the acquired GCT changes. In addition, by sampling the GCTs at the earliest 
possible time point when they are macroscopically visible (approximately 6 wks of age), 
the number of acquired mutations represented in the proteome is predicted to be low, 
indicating that any changes would have likely occurred at the time of tumour initiation. 
By looking at the expression of proteins essential for normal reproductive development 
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and function, insight into probable initiators in the early stages of the reproductive 
systems development can be gained.  
Each protein of interest has an established knowledge base in the current 
literature; however, little is known about their status in the rare JGCT condition. To 
establish a profile of confirmed GCTs from SWR mice, we compared them to the normal 
whole ovaries of unaffected female littermates. Proteins involved in the normal 
physiological processes of the ovary, such as Cyp19a, Fshr and Egfr provided a starting 
point of investigation.  
In age matched GCTs, Cyp19a (aromatase) and Fshr remained unchanged from 
their normal ovary controls, with a wide variation in the normal ovaries for Fshr, which 
could be to expression differences between individual mice due to their normal estrus 
cycles. This result was anticipated, since Cyp19a is upregulated by Fsh activation through 
the Fshr on the GC population and by regulation of Cyp19a by the transcription factor 
Foxl2 (Fleming et al. 2010). More support for sufficient Cyp19a expression in GCTs is 
the observation by Beamer et al. (1985) that the mice who develop the tumours are highly 
estrogenized, supported by the observation of thickened uteri, enlarged vaginal opening 
and a solid, large cervix. This indicates that Cyp19a is at a level that allows for continued 
E2 production.  
Another physiologically relevant protein of the ovary is Egfr, which was 
investigated by immunoblotting and compared between age-matched ovaries and 
individually collected, spontaneous GCTs. Egfr is expressed in normal mouse ovaries 
where it plays a role in the FSH pathway to stimulate folliculogenesis, leading to follicle 
recruitment (Hunzicker-Dunn & Maizels, 2006). A very significant up-regulation of Egfr 
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protein was measured in isolated protein lysates from early onset GCTs extracted from 
SWR-derived female congenic mice compared to normal ovary pairs from the littermate 
controls (Figure 3.3). Up-regulation of Egfr was consistent across individual mouse 
GCTs, to the point that equivalent protein loading led to signal saturation in the GCTs 
with minimal signal in the normal ovary at the equivalent exposure time (Figure 3.4). In 
the current study, blots are shown with minimal exposure for the intense JGCT bands and 
at a higher exposure for the normal ovaries and COV434 lysates (Figure 3.3 & Figure 
3.4, respectively). For future work it would be beneficial to load a proportion of the 
JGCT lysates to be able to analyze all samples at the same exposure time. In a previous 
study done with SWR mice, Tennent et al. (1989) found increased Egfr in GCTs 
compared to normal ovaries by a qualitative assessment of antibody-mediated 
immunofluorescence, as well as measuring EGF ligand binding capacity and proliferative 
response of short-term cultured tumour cells to EGF. My findings agree with the report of 
Tennent et al., regarding SWR-derived JGCTs observing a 10-fold increase in Egfr 
expression in JGCTs compared with normal ovary pairs. These results also agreed with 
general literature of Egfr, which indicates the overexpression, and upregulation of the 
protein in many types of cancers (Tennent et al. 1989, Andersson et al., 2014, Higgins et 
al., 2014). In this study, global Egfr expression was investigated; however, subtypes of 
Egfr have been indicated in other types of cancers, such as HER2 in breast cancer (Leibl 
et al. 2006). Using a global Egfr antibody only allowed for the investigation of all 
receptor subtypes (Her-1, Her-2, Her-3 and Her-4) but not the ligands of Egfr. By only 
investigating the global Egfr expression rather than the specific subtypes, I was unable to 
determine which subtypes specifically could be involved in the upregulation of Egfr in 
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JGCTs, limiting our specific knowledge of the tumours and possible treatment options. 
However, the dramatic upregulation in our tumour samples suggest an anti-EGFR therapy 
may be a viable option for JGCT. 
 Another group of proteins that were investigated included Foxl2, Esr2 and Sox9. 
Foxl2 and Sox9 are important for normal gonad specification in the female ovary and 
male testis, respectively, with expression patterns that are characteristically mutually 
exclusive, such that somatic cells of the developing gonads express only one or the other 
of these sex specification factors (Tanaka et al. 2014). Esr2 also plays an important role 
in ovarian specification and is the primary Er isoform expressed in ovarian GCs 
(Uhlenhaut et al., 2009). 
Based on prior knowledge of FOXL2 somatic mutation status in human AGCTs 
and consideration of the variation in overall expression status of wildtype FOXL2 in 
JGCTs, it was important to determine Foxl2 protein expression levels in the SWR derived 
tumours compared to the normal condition (Shah et al., 2009; Jamieson et al., 2010). In 
my investigation comparing protein lysates from normal ovary pairs to age-matched and 
genetic strain matched mouse GCTs, Foxl2 protein expression showed no significant 
difference between tumour samples and normal samples, demonstrating agreement 
between our mouse model and a proportion of JGCTs identified that retain a normal 
degree of nuclear Foxl2 expression as GCs of a normal ovary (Kalfa et al., 2007). One 
limitation of my study was the absence of IHC in mouse GCTs to confirm nuclear 
localization of the Foxl2 transcription factor. Matched samples of GCTs isolated for 
protein lysates were retained for IHC purposes, but the chosen method of fixation in 
paraformaldehyde (4 %) led to non-specific staining with IgG control antibody in two 
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different IHC protocols, with or without antigen retrieval (data not shown). Follow up 
experiments using optimized IHC fixation is required to confirm nuclear Foxl2 
localization in the mouse GCTs. 
 Kalfa et al. (2007) made the suggestion that retention of nuclear FOXL2 protein 
is associated with a less aggressive tumour presentation, although additional cohorts and 
clinical follow up would help support this conclusion. At the early sampling stage of 
mice aged 6 wks, only 2 -3 wks following GCT initiation at puberty, the mouse tumours 
sampled for protein lysates in this study are proliferative masses of GC tumour cells that 
have not yet acquired malignant properties. In the SWR mouse model, approximately half 
of the GCTs progress to hormone-independent growth and metastatic potential when the 
hosts are much older (> 6 months; Tennent et al., 1990). It is a future direction for this 
study to compare the protein expression profiles of the early GCTs identified here with 
late primary tumours or metastatic GCT foci sampled from older female mice, to address 
the translational hypothesis that Foxl2 protein expression would be diminished or lost 
with advanced malignancy. 
 Esr2, historically known as Estrogen receptor β, is necessary for the normal 
reproductive functioning of the ovary and is highly expressed in the GCs (Nalvarte et al. 
2016). Esr2 protein is an important developmental and physiological ovarian factor that 
showed a significant decrease in GCTs relative to lysates prepared from the normal 
mouse ovary. One of Esr2’s important functions is to support female gonad specification 
by contributing to Sox9 transcriptional suppression during ovarian development 
(Uhlenhaut et al., 2009). In terms of overall fertility phenotypes, Esr2 knockout mice are 
viable and the ovaries develop, but the females are subfertile compared to wildtype 
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controls due to a decrease in follicle maturation and ovulation (Couse et al., 2006; Jayes 
et al. 2014). The majority of SWR female mice without pubertal onset GCTs have normal 
fertility and reproductive history, suggesting Esr2 expression is sufficient in the 
unaffected ovaries (Dorward, unpublished). When both Estrogen receptor α (Esr1) and 
Esr2 are deleted in engineered mouse strains, testis-like structures and Sertoli-like cells 
appear in the mouse ovary, suggesting a cooperative role of the Er signaling network to 
maintain GC identity; however, GC tumour susceptibility is not observed (Couse et al., 
1999). Reduced expression of Esr2 in the SWR strain GCT samples suggests a tumour 
suppressor contribution of Esr2, with a potential influence on the androgen-sensitivity of 
the tumourigenic program (Beamer et al., 1988; Tennent et al., 1993; Dorward et al. 
2007). IHC follow up of GCT tissues would also determine if remaining Esr2 protein is 
mislocalized to the cytoplasm, contributing to imbalanced Er signaling. 
 During gonad specification, the Foxl2 and Sox9 transcription factors have 
prominent roles to support ovarian or testis development, respectively. Somatic cell 
expression of Foxl2 and Sox9 in the gonad is exclusive in this context, although some 
conditions can lead to a sex-specific switch of the gene expression profiles, where male-
to-female or female-to-male changes are observed, such as the female-to-male cellular 
transdifferentiation observed in the Esr1/Esr2 double knockout ovaries (Couse et al., 
1999). In the case of gonadal tumourigenesis, a population of Foxl2-expressing 
granulosa-like tumour cells may appear in the male testis that no longer express Sox9, as 
has been observed in several cases of Juvenile-type GCTs of the Testis (JGCTT; Kalfa et 
al., 2008). Of note, male mice of the SWR strain do not exhibit gonadal stromal tumours 
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in general, or JGCTTs specifically, indicating the Gct loci have sex-specific influence to 
trigger early onset GCTs only in the female ovary.  
The ovarian GCTs of SWR female mice had never been examined for Sox9 
expression so I approached this initially using an immunoblotting strategy. The protein 
expression profile of GCTs showed a significant overexpression of Sox9 using a 
polyclonal antibody for Sox9, similar positive control tissue lysates prepared from the 
prostate gland of the mature male mouse reproductive tract with high Sox9 expression 
(Ma, F et al. 2016; Figure 3.7A). The intensity of Sox9 expression in GCT lysates was an 
interesting and novel finding that was further investigated with a monoclonal antibody to 
the Sox9 protein useful for both immunoblotting and IHC. A increase in Sox9 expression 
was observed in mouse GCTs relative to normal ovary protein lysates using the 
monoclonal antibody however it was not significant and testis as a control tissue to 
ensure the accuracy and confirm the initial result from the polyclonal antibody (Figure 
3.7B).  
To address the limitation of looking at expression levels in the heterogeneous 
whole, ovary and comparing it to the GCT protein lysates that also have some protein 
contributions from other cell populations (blood, immune cells, vascular endothelial cells, 
etc.). I investigated the localization of the Sox9 expression in normal ovaries and JGCTs 
from female SWR-background mice and testis control tissue from male mice by IHC 
using the monoclonal antibody. Figure 3.8A and Figure 3.8B show H&E staining of 
normal ovary and testis, as well as Sox9 staining of these tissues with IgG as a control. A 
normal staining pattern is visible in the Sertoli and Leydig cells of the testis as expected 
(Daigle et al. 2015). In the normal ovary, Sox9 staining was observed in some stromal 
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cells located in the outside perimeter of maturing follicles; however, the GCs in follicles 
of all stages were negative for Sox9 staining (Figure 3.7A). This small contribution of 
Sox9 positive cells in the ovary likely contributes to the minor representation of Sox9 
detection in the normal ovary lysates with the immunobloting technique (Figure 3.7B). 
In addition to visualizing Sox9 expression in normal gonads, it was also explored 
in two additional JGCTs extracted from SWR-background female mice whose tissues 
were fixed in Bouin’s solution, permitting specific Sox9 detection. Figure 3.9A and 
Figure 3.9B represent two independent JGCTs collected from female mice at 8 wks of 
age. H&E staining shows the highly cellular nature of the tumours as opposed to the well 
organized follicle population of the ovary, with the majority of the ovarian mass taken up 
by the GC cells. Although these specimens were collected at “early” time points post-
initiation at 3-4 wks of age, some areas of necrosis are evident, where the GC 
proliferations presumably outpace vasculature development with restrictions to nutrient 
and oxygen supply. Sox9 expression was not consistent across the GCT, but was 
observed in a selection of cells throughout the two GCTs examined (Figure 3.9A & 
Figure 3.9B). There are several possibilities as to what these Sox9-positive tumour cells 
are and where they originated: 1) they may be the same Sox9-positive cells that were 
observed in the normal ovary but are now distributed throughout the GCT since the 
follicular structures are abolished; 2) due to leaky vasculature, the Sox9-positive cells 
may have migrated from other areas into the tumour environment, or 3) it is quite 
possible that these cells are indeed a subset of GC tumour cells that are now expressing 
Sox9.  Further exploration of this change in the expression of gonad specification factors 
of the mice is necessary to aid in the determination of GCT initiating factors such as 
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Gct1, the most influential tumour susceptibility locus identified in the SWR strain 
(Beamer et al., 1998; Dorward et al., 2005; Smith et al., 2013). Based on the expression 
for somatic cells of the gonad to express either Sox9 or Foxl2 and not both, a follow up 
of Foxl2 staining by IHC analysis in these GCT specimens is warranted, in addition to the 
markers already examined such as Egfr, Fshr and Esr2 to identify the Sox9 expressing 
cells as potential GCT cells (Figure 1.2).  
4.2 The normal ovary and a model human JGCT cell line, COV434 
 
COV434 cells were obtained directly from a public repository and maintained at 
low passage number to generate lysates for my protein-profiling investigation. A 
comparison of the COV434 cell line to the normal ovary in mice provides information on 
the status of the cell line as representative of GC tumour origin, akin to published 
findings by other research groups. The expression of the proteins of interest between the 
two conditions displayed a similar protein profile in both groups. Cyp19a, Fshr, Egfr, 
Foxl2 and Sox9 in normal, whole ovaries all showed equivalent expression levels with 
the JGCT cell line (Figure 3.1-3.4, Figure 3.6); however, in contrast with other groups, a 
distinct band indicating FOXL2 expression was present in the COV434 cell line which 
will be further discussed in section 4.3. The only protein that had a significantly 
decreased expression in the COV434 cell line was Esr2 having a 4-fold decrease from the 
normal ovary (Figure 3.5); it was interesting that this pattern was similar to the mouse-
derived GCTs, suggesting reduced Esr2 expression is important for JGCT 
tumourigenesis. The similarities in the expression levels of proteins important in GCs 
between normal, whole ovaries and the homogenous COV434 JGCT cell line helps to 
address the limitation of using the heterogeneous whole ovary, indicating that although 
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many cell types were present in the immunoblotting analysis, the comparable levels of 
the proteins with a GC specific cell line aids in the confirmation of GC specific 
expression in the whole ovary lysates. 
 
4.3 The Mouse GC tumour and a model human GCT cell line, COV434 
	  
COV434 is an accepted JGCT cell line was used as a comparison to GCTs from 
the SWR mouse model to determine similarities and differences between the proteins of 
interest. The three physiological proteins investigated, CYP19A, FSHR and EGFR, 
varied in their comparison to the primary mouse GCTs. It is important to recognize that 
in both the mouse JGCTs and the COV434 cell line, some level of expression of the GC 
proteins of interest are present, but the expression levels may vary between the two 
models. An example of this is the expression of CYP19A; both primary GCT lysates and 
the COV434 cells have detectable CYP19A expression, which showed a significant 
upregulation in COV434 lysates when compared to the GCTs. It is unclear if this is a 
species-specific difference and our hypothesis that both models of JGCT would have a 
similar protein expression profile is not completely in disagreement with the observed 
results as there are many reasons for some of the quantitative differences. This result 
however is somewhat expected as it has previously been found that the human JGCT 
condition is characterized by increased E2 production by the tumour, which is also noted 
in SWR female mice that have hormonally active GCTs, leading to premature 
menstruation indicating that the increase in CYP19A expression in the COV434 cell line 
leads to increased E2 production in the human condition (Beamer et al., 1988; Karalök et 
al. 2015). This increase in CYP19A expression supports my hypothesis that COV434 
cells and JGCTs from SWR mice would have a similar expression profile. The only 
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protein from this group which had equivalent expression between GCTs and the COV434 
lysates was FSHR.  
One exception was the observation for EGFR, which had such a significant up-
regulation in mouse GCTs. In terms of EGFR protein, a significantly lower expression 
was observed in the cells compared to the GCT samples (Figure 3.3), which had high 
overexpression and it appears to be not present at all when immunoblots were adequately 
exposed. In agreement with our hypothesis, that protein expression between the GCTs 
and COV434 cell line would be similar, was the expression of Fshr. Since we would 
predict that there would be little or no difference between the mouse GCTs and the 
representative human JGCT cell line, the absence of any change in FSHR expression in 
COV434 cells supported this prediction. 
Of the three-gonad specification proteins studied, one protein that has been 
previously investigated in COV434 cells is FOXL2 due to the important role it plays in 
the development of the adult form of GC tumours. In previous studies, FOXL2 protein 
status was investigated and no expression was detected by IHC in the COV434 cell line 
(Jamieson et al., 2010; Rosario et al. 2013). This did not agreed with what I observed, 
which was FOXL2 expression in the cell line as well as in GCTs, with no significant 
difference between the two groups. The other two proteins, ESR2 and SOX9, both had a 
significant downregulation in the homogenous COV434 cell lysates relative to the 
primary mouse GCTs that are more heterogeneous in nature.  
COV434 lysates were negative for SOX9 expression, with a significant band 
observed in the mouse GCT lysates. There was an intense expression observed at a higher 
Mr than what was expected from the polyclonal antibody product sheet (Santa Cruz, H90) 
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and was also higher than the expected Mr of Sox9. A faint band was also observed at the 
correct Mr compared to the stained protein ladder. To be convinced that this was just non-
specific binding of the antibody and not Sox9 migrating at a higher Mr in human samples, 
a monoclonal Sox9 antibody (Cell Signaling Technology, D8G8H) was tested by 
immunoblotting as well as by IHC, confirming the specificity of the antibody and that the 
appropriate band was analyzed. The monoclonal Sox9 antibody was confirmed as highly 
specific by the staining pattern of the Sertoli cells of the testis after IHC. In addition to 
this experimental result, a literature search was performed and no reports of species-
specific size differences were found. 
ESR2 expression was significantly down-regulated in the COV434 lysates 
compared to the mouse GCT lysates whereas in normal ovaries, ESR2 was significantly 
higher. This down-regulation of ESR2 in the two GCT representative lysates may 
indicate a reduced expression of the tumour suppressor. To confirm the nuclear 
localization and functionality of the ESR2 protein, IHC or cell staining is needed in the 
future. 
We would expect that the protein expression profile of the COV434 cell lysates 
and the JGCT samples to be similar as the cell line is representative of JGCTs, although 
species differences could have attributed to some of the quantitative differences in the 
mouse tumours and the human cell lysates. Although some expression differences in 
Cyp19a, Esr2, Egfr and Sox9 were observed in the COV434 cell lysates, the cell model is 
still considered in the literature and in this study to be representative of the human JGCT 
condition although perhaps not a perfect model of the disease. This characterization is 
supported by work done in IVF patients that provide evidence that the COV434 cell line 
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exhibit properties of GCs including the production of E2 in response to FSH, as well as 
their ability to form connections with other cells around the oocyte (Zhang et al. 2000). 
With this evidence supporting the JGCT status of the cell line, it continues to be the best 
human model available. Unfortunately due to the rare nature of human JGCTs, 
accounting for only approximately 5 % of all GCTs, which are a rare subtype of ovarian 
cancer, a comparison of the COV434 cell line with primary human JGCTs has not been 
done to definitively determine its status. However, the expression status of several 
proteins of interest have been explored in human JGCTs. Over half of AGCTs and 
JGCTs surveyed were found to be positive for Egfr expression by IHC analysis (Leibl et 
al. 2006). Another protein that has been extensively studied in human JGCTs is FOXL2. 
One group who looked at human FOXL2 expression by IHC found expression to be 
normal in half of the cases they looked at while the other half, the more aggressive cases 
had absent or markedly reduced FOXL2 expression in human JGCTs (Kalfa et al. 2007). 
However, although some human samples were found to have normal FOXL2 expression, 
three other groups have also reported no or very low FOXL2 gene expression in the 
COV434 cell line, in contrast to what I found by immunoblotting (Fleming et al., 2010; 
Jamieson et al., 2010; Rosario et al., 2013). By comparing these two models, new insight 
into the actual source of the COV434 cell line could be identified and possibly 
investigated in the future. If COV434 is indeed a JGCT cell line, as reported, other 
factors can be contributing to the differences we have seen. Besides species variations, 
the cell line may have new adaptations to its artificial environment that tissue samples 
would not have acquired. To minimize these possible changes, the COV434 cell line was 
directly imported from the repository and expression levels were measured at a low 
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passage number to reduce the number of acquired changes. Another important distinction 
between the SWR JGCT samples and the COV434 cell line is the mouse tumours are 
identified as benign, non-metastatic lesions at the point of extraction; however, the 
COV434 cell line was developed from borderline malignant, metastatic lesion, which 
may have acquired a unique protein expression signature from the primary patient tumour 
at the time of its initial occurrence that contributed to its later malignant, metastatic 
nature (Van Den Berg-Bakker et al., 1993, Zhang et al., 2000). A better comparison may 
be to sample the mouse GCTs at a later time point, when they are malignant (Tennent et 
al., 1990) and have potentially developed alterations similar to what is observed in the 
COV434 cell line. There is little currently known about the protein expression profile of 
COV434 cells compared to the established SWR mouse model, thus much of what was 




The SWR mouse model of juvenile GC tumourigenesis provides a valuable 
resource to study not only the genetics of JGCTs but also their protein expression 
profiles. By investigating the various proteins involved in both ovarian physiology and 
gonad specification, we were able to gain new insights into the developmental processes 
when tumour initiation occurs, such as the possible alterations to the factors involved in 
the normal progression of the bipotential gonad formation to the ovaries indicated by the 
downregulation of Esr2 and presence of Sox9 positive cells that need to be investigated 
as bystander cells, or GC cells that have exchanged Foxl2 expression for Sox9 during the 
tumourigenic transition. In addition to new information, we were also able to confirm 
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what others have previously observed, for instance an increase of Egfr expression in 
GCTs. We were also able to confirm normal status of Cyp19a and Fshr between 
experimental groups. The comparison of GCTs to COV434 lysates provided new 
information about the status of Cyp19a, Egfr, Esr2 and Sox9, which we hypothesized to 
be similar but turned out to vary in their expression. Lastly, a comparison of the normal 
ovary of mice to the human COV434 cell line also showed many similarities that could 
be attributed to mutational status of the cell line or to species differences as with the GCT 
variability. This profile provides us with valuable insights into the status of JGCTs and is 
a good starting point to allow a basis for future investigations. 
6.0 Future Directions 
	  
	   The next step in these investigations of JGCTs would be to continue building the 
protein expression profile of the tumour. Identification of other proteins of interest by 
looking at targets potentially altered upstream of Esr2 and Sox9 and then performing 
immunoblotting to determine protein expression levels and IHC of all proteins of interest 
to visualize the localization of each protein to their specific cell type would build on the 
knowledge we have gained here to investigate the potential effect on bipotential gonad 
development. Also, by performing IHC to confirm cell types that are Sox9-positive by 
looking at proteins specific to each cell type, for example Cyp19a in GCs and Cy17a1 in 
TCs. With the theory of two follicle waves, it is possible that follicles that develop GCTs 
come from the first wave of follicles, which have a limited contribution to reproductive 
fertility, and these follicles have lower Esr2 expression, whereas the second wave, which 
are the primary source of fertility, have normal Esr2 expression (Zheng et al., 2014). 
Further exploration of these specific follicle populations by sampling GCTs at early and 
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late developmental timepoints and tracking cellular populations by IHC would provide 
valuable insights into the origin of JGCTs. Also, to further address the limitations of 
using whole ovaries, isolation of GCs and culture of those cells to look specifically at that 
cellular population would provide more specific details about their protein expression 
profile.  
 In addition to the protein profile, investigating any genetic alterations in the 
factors explored for protein expression could aid in the narrowing of candidates for Gct1. 
An interesting experiment to expand our knowledge of how the mouse JGCTs compare to 
the human condition would be to sample malignant tumours in the mice, by sampling a 
later time point and performing IHC to visualize the localized protein expression of 
specific tumour-initiating follicles, specifically looking at the three proteins that had 
extreme profiles; Esr2, Egfr and Sox9. A focused technique such as this would aid in the 
establishment of differences in tumour status that contribute to the differences we 
observed. Egfr can also be investigated further by doing more targeted expression 
analysis looking at subtypes including Her-1 and Her-2, especially those that are 
indicated in other cancers, leading to possible treatment options. Another interesting 
angle would be to look at the upstream enzyme of Cyp19a, 3β- HSD, to investigate its 
status that could lead to the buildup of androgens that lead to tumour development 
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Appendix B Summary of inventoried samples 
	  











22 SWR x SWR.CAST-X1 (F1) 22099 07/05/13 08/19/13 
23 SWR x SWR.CAST-X1 (F1) 22142 08/05/13 09/16/13 
24 SWR x SWR.CAST-X1 (F1) 22143 08/05/13 09/16/13 
25 SWR x SWR.CAST-X1 (F1) 22158 08/20/13 10/03/13 
26 SWR x SWR.CAST-X1 (F1) 22159 08/20/13 10/03/13 
31 SWR x SWR.CAST-X1 (F1) 22190 09/11/13 10/23/13 
32 SWR x SWR.CAST-X1 (F1) 22191 09/11/13 10/23/13 
33 SWR x SWR.CAST-X1 (F1) 22192 09/11/13 10/23/13 
37 SWR x SWR.CAST-X1 (F1) 22174 09/02/13 10/15/13 
38 SWR x SWR.CAST-X1 (F1) 22175 09/02/13 10/15/13 
39 SWR x SWR.CAST-X1 (F1) 22176 09/02/13 10/15/13 
40 SWR x SWR.CAST-X1 (F1) 22177 09/02/13 10/15/13 
41 SWR x SWR.CAST-X1 (F1) 22178 09/02/13 10/15/13 
42 SWR x SWR.CAST-X1 (F1) 22470 04/16/14 06/25/14 
43 SWR x SWR.CAST-X1 (F1) 22471 04/16/14 06/25/14 
44 SWR x SWR.CAST-X1 (F1) 22472 04/16/14 06/25/14 
45 SWR x SWR.CAST-X1 (F1) 22473 04/16/14 06/25/14 
46 SWR x SWR.CAST-X1 (F1) 22489 05/01/14 06/25/14 
47 SWR x SWR.CAST-X1 (F1) 22493 05/01/14 06/25/14 
48 SWR x SWR.CAST-X1 (F1) 22491 05/01/14 06/25/14 















Strain Animal ID # Date of Birth Date of Necropsy 
1 SWR x SWR.CAST-X1 (F1) 22100 07/05/13 08/19/13 
3 SWR x SWR.CAST-X1 (F1) 21875 01/04/13 02/18/13 
4 SWR x SWR.CAST-X1 (F1) 21876 01/04/13 02/18/13 
11 SWR. CAST-X1 22094 06/30/13 09/02/13 
12 SWR. CAST-X1 22140 07/29/13 09/09/13 
13 SWR x SWR.CAST-X1 (F1) 21976 03/28/13 05/13/13 
14 SWR x SWR.CAST-X1 (F1) 21977 03/28/13 05/13/13 
15 SWR x SWR.CAST-X1 (F1) 21978 03/28/13 05/13/13 
17 SWR. CAST-X1 22092 06/30/13 09/02/13 
21 SWR x SWR.CAST-X1 (F1) 22227 09/24/13 11/08/13 
24 SWR x SWR.CAST-X1 (F1) 22309 11/16/13 01/09/14 
25 SWR x SWR.CAST-X1 (F1) 22313 11/16/13 01/10/14 
27 SWR x SWR.CAST-X1 (F1) 22297 11/16/13 01/10/14 
28 SWR x SWR.CAST-X1 (F1) 22488 05/01/14 06/25/14 












Table B.3 Summary of cell lysate samples from the human cell line COV434 analyzed 
by immunoblotting. 
	  












Table B.4 Summary of tissues from mice for analysis by IHC. 
 
Tissue Type Tissue Treatment 
Testis Untreated 
Normal Ovary DHEA-treated 
GCT DHEA-treated 
GCT DHEA-treated 
	  
 
 
 
 
 
 
 
 
 
